Bicuspid aortic valve: Basics and beyond

Article Type
Changed
Tue, 10/01/2019 - 08:32
Display Headline
Bicuspid aortic valve: Basics and beyond

Bicuspid aortic valve may initially be asymptomatic, but it is associated with progressive valvular and aortic abnormalities that can lead to chronic heart failure and sudden death. Regular monitoring is required with an eye toward surgery when indicated.

See related editorial

This article reviews inheritance patterns and conditions associated with bicuspid aortic valve. We discuss diagnosis, management, and monitoring, and offer surgical recommendations. Special guidance for dental procedures, pregnancy, and athletes is also provided.

A YOUNG MAN WITH PALPITATIONS AND A MURMUR

A 34-year-old man presented to an outpatient clinic with occasional palpitations over the past several months. He reported that he had been diagnosed with a murmur as a child but had received no further testing.

Physical examination at this time revealed a faint systolic crescendo-decrescendo murmur along the right sternal border without radiation to the carotid arteries or to the apex. Transthoracic echocardiography (TTE) showed a bicuspid aortic valve with fusion of the right and left coronary cusps, with no aortic valve stenosis or insufficiency. There was mild dilation of the aortic root, but the mid-ascending aorta could not be evaluated because of limited acoustic windows.

Is further diagnostic testing needed, and if so, what? May he participate in exertional physical activity? Does his newborn son need evaluation?

ABNORMALITIES OCCUR DURING EMBRYOGENESIS

Bicuspid aortic valve develops because of abnormal valvulogenesis. Adjacent cusps fail to separate from each other, resulting in only 2 cusps, with 1 usually larger than the other. Morphology varies according to which commissures are fused.1

Bicuspid aortic valve is associated with abnormalities in the coronary artery anatomy in about 2% of patients, including anomalous origins of the coronary arteries and upwardly displaced coronary ostia.2 Such features need to be considered before surgical intervention.

Bicuspid aortic valve can be found in 1% to 2% of the general population, with a male-to-female predominance of 3:1.1,3,4 It is one of the most common congenital cardiac malformations and is the leading congenital cause of aortic valve stenosis.1,3 However, routine screening of newborns for the condition is not recommended, and most cases are diagnosed incidentally.

GENETIC FACTORS PROMINENT

Bicuspid aortic valve is thought to be primarily inherited in an autosomal-dominant pattern, but there is evidence of genetic heterogeneity, and the pattern may be variable.5,6

No single gene responsible for bicuspid aortic valve has been identified. The condition may occur as a component of different pleiotropic genetic syndromes such as Loeys-Dietz, DiGeorge, and Marfan syndromes,7,8 as well as in patients with Turner syndrome and Williams syndrome.8–11 It also commonly coexists with other congenital heart diseases, including ventricular septal defect, isolated aortic arch obstruction, and patent ductus arteriosus.9

Studies have found a 15% rate of familial clustering.6,12 In a study of 142 patients with bicuspid aortic valve, 20% of first-degree relatives had some cardiac abnormality found by screening, of whom 68% had bicuspid aortic valve. Of these, 71% were newly detected abnormalities.13

CHARACTERISTIC CLICK AND MURMUR

Physical examination findings of a functionally normal bicuspid aortic valve include a systolic ejection click followed by an early peaking systolic murmur at the apex or left lower sternal border. With progression of aortic stenosis, the ejection murmur has a harsher sound, with later peaking, and the S2 sound diminishes or becomes inaudible.14 If aortic regurgitation is present, a diastolic decrescendo murmur is heard best at the left lower sternal border.

 

 

DISEASE PROGRESSION

Although bicuspid aortic valve is typically asymp­tomatic at first, it is commonly associated with progressive valvulopathy and thoracic aortic disease.1,3,4,15 It can lead to chronic heart failure and increase the risk of acute aortic syndromes and sudden cardiac death.15

Michelena et al16 studied 212 cases of asymp­tomatic bicuspid aortic valve. Although the survival rate 20 years after diagnosis was the same as for an age-matched cohort in the general population, the frequency of adverse cardiovascular events and surgical interventions was higher.

Aortic stenosis progresses rapidly

Aortic stenosis associated with a bicuspid aortic valve tends to affect younger patients and progress more rapidly than when associated with a tricuspid valve.17

In a study of 542 patients with congenital bicuspid aortic valve undergoing aortic valve replacement,3 75% had isolated aortic stenosis, 10% had aortic stenosis with some degree of aortic insufficiency, and 13% had isolated aortic insufficiency. Given the tendency of aortic stenosis to progress rapidly, early surgery is often pursued.17,18

Aneurysmal disease is common

The thoracic aorta is at increased risk of aneurysmal disease, coarctation, and dissection in patients with a bicuspid aortic valve.1,6,15

Michelena et al16 reported that in patients without an aneurysm at the time of bicuspid aortic valve diagnosis, the 25-year risk of aneurysm formation was approximately 26%. In patients with an aneurysm at the time of diagnosis, the 15-year risk of aortic surgery after the diagnosis of aneurysm was about 46% and the risk of aortic dissection after aneurysm diagnosis was 7%.15 Compared with the general population, the age-adjusted relative risk of aortic aneurysm in patients with bicuspid aortic valve was 86.2, and that of aortic dissection was 8.4. Although the absolute incidence of dissection is low in these patients, it is markedly higher than in the general population, particularly in older patients (age > 50) and those with an aneurysm at the time of diagnosis.15

The risk of infective endocarditis

Patients with bicuspid aortic valve are highly prone to infective endocarditis for reasons that remain poorly understood. The pathogens in most cases are staphylococci or viridans streptococci.19 Patients with infective endocarditis typically require emergency surgery. Complications including valvular abscess, myocardial abscess, and overt heart failure are common.19

Lamas and Eykyn20 studied 408 cases of native valve endocarditis; in 12.3%, the patient had a bicuspid aortic valve. In this subset, all were male, the mean age was 39 at diagnosis, 82% needed surgery, and the death rate was 14%.

Patients with bicuspid aortic valve do not routinely need antibiotics before dental and surgical procedures, but if they have had endocarditis in the past, they need antibiotics to prevent a recurrence.21

REGULAR MONITORING NEEDED

Because complications may be life-threatening, early detection of progressive disease by regular screening is critical. Echocardiographic evaluation of valvular function, ventricular dimensions and function, and diameter of the aortic root and ascending aorta should be performed in every patient with bicuspid aortic valve. If initial imaging is normal and there is no aortic dilation, imaging should be repeated every 5 to 10 years. If any abnormality is found, repeat imaging is needed every year.22

Transthoracic echocardiography
Figure 1. Transthoracic echocardiography, parasternal long-axis view, shows a dilated aortic root (AR) measuring 4.5 cm in a patient with bicuspid aortic valve (arrows). AA, ascending aorta; LA, left atrium; LV, left ventricle.

Two-dimensional transesophageal echocardiography
Figure 2. Two-dimensional transesophageal echocardiography demonstrates an anterior-posterior bicuspid aortic valve (opening phase, arrows). RA, right atrium; LA, left atrium; RV, right ventricle.

Magnetic resonance imaging (MRI) or computed tomographic (CT) angiography may be required to better assess the aorta for patients requiring a surgical intervention, or when aortic dimensions are not clearly visualized on TTE. MRI has 2 advantages over CT angiography: it poses no radiation risk, and it provides more information on left ventricular function and dimensions, in addition to valve assessment.23,24

No published study has compared MRI or CT angiography and transesophageal echocardiography (TEE), but in a study of 174 patients with dilated aortic root, combined TTE and TEE detected aortic valve morphology accurately in 98% of cases. As TEE is more invasive, it is not recommended for regular surveillance (Figures 1 and 2).25

FAMILY SCREENING RECOMMENDED

Close relatives should be evaluated for aortic valve and thoracic aortic disease.12,13,23,26

The American College of Cardiology (ACC) and the American Heart Association (AHA), backed by radiologic and cardiovascular associations, concur in recommending echocardiographic screening and routine screening of the thoracic aorta for aortic root dilation in first-degree relatives (ie, siblings, parents, and children) of patients with bicuspid aortic valve (class I recommendation).22,27,28

A comprehensive physical examination is recommended for family members in addition to TTE, with careful assessment of the aortic valve in short and long axes, and of the aortic root.14 If the aorta cannot be adequately evaluated with TTE, further assessment should be pursued with CT angiography or MRI.

 

 

EXERCISE RESTRICTIONS

The 2015 ACC/AHA guidelines for competitive athletes with cardiovascular abnormalities recommend annual screening with TTE or MRI angiography for athletes with bicuspid aortic valve and coexisting dilation of the ascending aorta (aortic diameter 40–42 mm in men and 36–39 mm in women) (class I recommendation, level of evidence C).29

Athletes with a bicuspid aortic valve and a normal aortic root and ascending aorta may participate in all competitive activities.29 However, those with a dilated aorta should avoid strenuous activities because of the increased risk of rupture.30 The ACC/AHA recommendations29 depend on the diameter of the ascending aorta and the nature of the sport:

  • For an aortic diameter 40 to 42 mm in men or 36 to 39 mm in women, and no features of connective tissue disease or familial thoracic ascending aortic syndrome, low- and moderate-intensity sports with a low likelihood of significant body contact may be considered; consider avoiding intense weight training (class IIb, level of evidence C)
  • For an aortic diameter 43 to 45 mm, low-intensity sports with a low likelihood of body contact may be considered (class IIb, level of evidence C)
  • For an aortic diameter greater than 43 mm in men or greater than 40 mm in women, sports involving body collision should be avoided (class III, level of evidence C)
  • For an aortic diameter greater than 45 mm, sports activities should be avoided (class III, level of evidence C).

PREGNANCY CONSIDERATIONS

Bicuspid aortic valve is associated with aortic dissection, mainly in the third trimester.31 Patients should ideally undergo echocardiographic screening before conception. The 2010 ACC/AHA guidelines for managing thoracic aortic disease recommend monthly or bimonthly echocardiography until delivery in pregnant women with a dilated thoracic aorta.22

Patients with bicuspid aortic valve and aortic root enlargement of more than 40 mm should have preconception counseling about surgery for aortic root replacement before becoming pregnant. If the diagnosis of enlarged aortic root is made during pregnancy, echocardiographic surveillance at 4- to 6-week intervals is indicated.32

SURGICAL MANAGEMENT

In the past, beta-blockers and angiotensin-converting enzyme inhibitors were recommended to minimize shear stress, with the goal of slowing progression of aortic dilation. However, evidence to support their use is inadequate.33,34

The only definitive treatment is surgery, with various procedures that lower the risk of death or dissection.24,35

The dimensions of the aortic root or ascending aorta should be examined vigilantly, according to the 2014 ACC/AHA guidelines27:

  • Repairing the aortic sinuses or replacing the ascending aorta is indicated if the diameter of the aortic sinuses or ascending aorta is greater than 5.5 cm (class I, level of evidence B)
  • Repairing the aortic sinuses or replacing the ascending aorta is reasonable if the diameter of the aortic sinuses or ascending aorta is greater than 5.0 cm and the patient has a risk factor for dissection such as a family history of aortic dissection or an increase in diameter of 0.5 cm or greater per year (class IIa, level of evidence C)
  • Replacement of the ascending aorta is reasonable if the diameter of the ascending aorta is greater than 4.5 cm and the patient is undergoing aortic valve surgery for severe aortic stenosis or regurgitation.

Valve repair or replacement

Aortic valve repair or replacement is sometimes done separately from aortic root repair.

The value of aortic valve repair is debatable, but a series of 728 patients at Cleveland Clinic showed a very low mortality rate (0.41%) and an annual reoperation rate of 2.6% during up to 15 years of follow-up.36

Aortic valve replacement is usually considered for patients with severe valve dysfunction, abnormal left ventricular dimensions, or symptoms. It is important to determine if the patient is a good surgical candidate and to refer early for surgical evaluation to avoid the higher risk of death associated with emergency surgery.36

Transcatheter aortic valve replacement has been studied in patients deemed to be at too high a risk for surgical replacement. Short- and intermediate-term outcomes have been good in these patients, but long-term data are lacking.37

Surveillance after surgery

The type of operation determines postoperative surveillance.

After isolated aortic valve repair or replacement, patients should continue with surveillance at least annually to monitor for progressive aortopathy, as they remain at increased risk of dissection or rupture after isolated valve surgery, especially if they had aortic insufficiency preoperatively.38

After definitive surgery with replacement or repair of the ascending aorta, no clear recommendations have been established for continued surveillance. However, it is reasonable to image these patients with either MRI or CT angiography 3 to 5 years after their surgery to monitor for anastomotic complications.

CASE QUESTIONS ANSWERED

Our patient should undergo repeat TTE in 1 year. He should also undergo CT angiography of the ascending aorta if it is not seen by TTE. He can participate in low-intensity sports but should avoid intense weight training. His parents, siblings, and children should be screened for bicuspid aortic valve or associated aortopathies.

References
  1. Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am J Cardiol 1970; 26(1):72–83. pmid:5427836
  2. Michalowska IM, Hryniewiecki T, Kwiatek P, Stoklosa P, Swoboda-Rydz U, Szymanski P. Coronary artery variants and anomalies in patients with bicuspid aortic valve. J Thorac Imaging 2016; 31(3):156–162. doi:10.1097/RTI.0000000000000205
  3. Sabet HY, Edwards WD, Tazelaar HD, Daly RC. Congenitally bicuspid aortic valves: a surgical pathology study of 542 cases (1991 through 1996) and a literature review of 2,715 additional cases. Mayo Clin Proc 1999; 74(1):14–26. doi:10.4065/74.1.14
  4. Tutar E, Ekici F, Atalay S, Nacar N. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. Am Heart J 2005; 150(3):513–515. doi:10.1016/j.ahj.2004.10.036
  5. Benson DW. The genetics of congenital heart disease: a point in the revolution. Cardiol Clin 2002; 20(3):385–394. pmid:12371007
  6. Emanuel R, Withers R, O’Brien K, Ross P, Feizi O. Congenitally bicuspid aortic valves. Clinicogenetic study of 41 families. Br Heart J 1978; 40(12):1402–1407. pmid:737099
  7. Giusti B, Sticchi E, De Cario R, Magi A, Nistri S, Pepe G. Genetic bases of bicuspid aortic valve: the contribution of traditional and high-throughput sequencing approaches on research and diagnosis. Front Physiol 2017; 8:612. doi:10.3389/fphys.2017.00612
  8. Sachdev V, Matura LA, Sidenko S, et al. Aortic valve disease in Turner syndrome. J Am Coll Cardiol 2008; 51(19):1904–1909. doi:10.1016/j.jacc.2008.02.035
  9. Duran AC, Frescura C, Sans-Coma V, Angelini A, Basso C, Thiene G. Bicuspid aortic valves in hearts with other congenital heart disease. J Heart Valve Dis 1995; 4(6):581–590. pmid:8611973
  10. De Rubens Figueroa J, Rodríguez LM, Hach JL, Del Castillo Ruíz V, Martínez HO. Cardiovascular spectrum in Williams-Beuren syndrome: the Mexican experience in 40 patients. Tex Heart Inst J 2008; 35(3):279–285. pmid:18941598
  11. Yuan SM, Jing H. The bicuspid aortic valve and related disorders. Sao Paulo Med J 2010; 128(5):296–301. pmid:21181071
  12. Cripe L, Andelfinger G, Martin LJ, Shooner K, Benson DW. Bicuspid aortic valve is heritable. J Am Coll Cardiol 2004; 44(1):138–143. doi:10.1016/j.jacc.2004.03.050
  13. Kerstjens-Frederikse WS, Sarvaas GJ, Ruiter JS, et al. Left ventricular outflow tract obstruction: should cardiac screening be offered to first-degree relatives? Heart 2011; 97(15):1228–1232. doi:10.1136/hrt.2010.211433
  14. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol 2010; 55(25):2789–2800. doi:10.1016/j.jacc.2009.12.068
  15. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011; 306(10):1104–1112.
  16. Michelena HI, Desjardins VA, Avierinos JF, et al. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation 2008; 117(21):2776–2784. doi:10.1161/CIRCULATIONAHA.107.740878
  17. Beppu S, Suzuki S, Matsuda H, Ohmori F, Nagata S, Miyatake K. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valves. Am J Cardiol 1993; 71(4):322–327. pmid:8427176
  18. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005; 111(7):920–925. doi:10.1161/01.CIR.0000155623.48408.C5
  19. Yener N, Oktar GL, Erer D, Yardimci MM, Yener A. Bicuspid aortic valve. Ann Thorac Cardiovasc Surg 2002; 8(5):264–267. pmid:12472407
  20. Lamas CC, Eykyn SJ. Bicuspid aortic valve—a silent danger: analysis of 50 cases of infective endocarditis. Clin Infect Dis 2000; 30(2):336–341. doi:10.1086/313646
  21. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation 2007; 116(15):1736–1754. doi:10.1161/CIRCULATIONAHA.106.183095
  22. Hiratzka L, Bakris G, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. Circulation 2010; 121(13):e266–e369. doi:10.1161/CIR.0b013e3181d4739e
  23. Chun EJ, Choi SI, Lim C, et al. Aortic stenosis: evaluation with multidetector CT angiography and MR imaging. Korean J Radiol 2008; 9(5):439–448. doi:10.3348/kjr.2008.9.5.439
  24. Kiefer TL, Wang A, Hughes GC, Bashore TM. Management of patients with bicuspid aortic valve disease. Curr Treat Options Cardiovasc Med 2011; 13(6):489–505. doi:10.1007/s11936-011-0152-7
  25. Alegret JM, Palazon O, Duran I, Vernis JM. Aortic valve morphology definition with transthoracic combined with transesophageal echocardiography in a population with high prevalence of bicuspid aortic valve. Int J Cardiovasc Imaging 2005; 21(2-3):213–217. doi:10.1007/s10554-004-3901-9
  26. Biner S, Rafique AM, Ray I, Cuk O, Siegel RJ, Tolstrup K. Aortopathy is prevalent in relatives of bicuspid aortic valve patients. J Am Coll Cardiol 2009; 53(24):2288–2295. doi:10.1016/j.jacc.2009.03.027
  27. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Thorac Cardiovasc Surg 2014; 148(1):e1-e132. doi:10.1016/j.jtcvs.2014.05.014
  28. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. J Am Coll Cardiol 2008; 52(23):e143–e263. doi:10.1016/j.jacc.2008.10.001
  29. Braverman AC, Harris KM, Kovacs RJ, Maron BJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 7: aortic diseases, including Marfan syndrome. Circulation 2015; 132(22):e303–e309. doi:10.1161/CIR.0000000000000243
  30. De Mozzi P, Longo UG, Galanti G, Maffulli N. Bicuspid aortic valve: a literature review and its impact on sport activity. Br Med Bull 2008; 85:63–85. doi:10.1093/bmb/ldn002
  31. Thorne SA. Pregnancy in heart disease. Heart 2004; 90(4):450–456. pmid:15020530
  32. Immer FF, Bansi AG, Immer-Bansi AS, et al. Aortic dissection in pregnancy: analysis of risk factors and outcome. Ann Thorac Surg 2003; 76(1):309–314. pmid:12842575
  33. Allen BD, Markl M, Barker AJ, et al. Influence of beta-blocker therapy on aortic blood flow in patients with bicuspid aortic valve. Int J Cardiovasc Imaging 2016; 32(4):621–628. doi:10.1007/s10554-015-0819-3
  34. Ohnemus D, Oster ME, Gatlin S, Jokhadar M, Mahle WT. The effect of angiotensin-converting enzyme inhibitors on the rate of ascending aorta dilation in patients with bicuspid aortic valve. Congenit Heart Dis 2015; 10(1):E1–E5. doi:10.1111/chd.12184
  35. Masri A, Kalahasti V, Alkharabsheh S, et al. Characteristics and long-term outcomes of contemporary patients with bicuspid aortic valves. J Thorac Cardiovasc Surg 2016; 151(6):1650–1659.e1. doi:10.1016/j.jtcvs.2015.12.019
  36. Svensson LG, Al Kindi AH, Vivacqua A, et al. Long-term durability of bicuspid aortic valve repair. Ann Thorac Surg 2014; 97(5):1539–1548. doi:10.1016/j.athoracsur.2013.11.036
  37. Mylotte D, Lefevre T, Sondergaard L, et al. Transcatheter aortic valve replacement in bicuspid aortic valve disease. J Am Coll Cardiol 2014; 64(22):2330–2339. doi:10.1016/j.jacc.2014.09.039
  38. Girdauskas E, Disha K, Raisin HH, Secknus MA, Borger MA, Kuntze T. Risk of late aortic events after an isolated aortic valve replacement for bicuspid aortic valve stenosis with concomitant ascending aortic dilation. Eur J Cardiothorac Surg 2012; 42(5):832–838. doi:10.1093/ejcts/ezs137
Article PDF
Author and Disclosure Information

Shailee Y. Shah, MD
Department of Internal Medicine, Cleveland Clinic

Andrew Higgins, MD
Heart and Vascular Institute, Cleveland Clinic

Milind Y. Desai, MD
Haslam Family Endowed Chair in Cardiovascular Medicine, Department of Cardiovascular Medicine, Heart and Vascular Institute, and Department of Diagnostic Radiology, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Address: Shailee Y. Shah, MD, Department of Internal Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; shahs10@ccf.org

Issue
Cleveland Clinic Journal of Medicine - 85(10)
Publications
Topics
Page Number
779-784
Legacy Keywords
bicuspid aortic valve, BAV, aorta, aortopathy, echocardiography, stenosis, aneurysm, Loeys-Dietz syndrome, Marfan syndrome, DiGeorge syndrome, Turner syndrome, Williams syndrome, infective endocarditis, Shailee Shah, Andrew Higgins, Milind Desai
Sections
Author and Disclosure Information

Shailee Y. Shah, MD
Department of Internal Medicine, Cleveland Clinic

Andrew Higgins, MD
Heart and Vascular Institute, Cleveland Clinic

Milind Y. Desai, MD
Haslam Family Endowed Chair in Cardiovascular Medicine, Department of Cardiovascular Medicine, Heart and Vascular Institute, and Department of Diagnostic Radiology, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Address: Shailee Y. Shah, MD, Department of Internal Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; shahs10@ccf.org

Author and Disclosure Information

Shailee Y. Shah, MD
Department of Internal Medicine, Cleveland Clinic

Andrew Higgins, MD
Heart and Vascular Institute, Cleveland Clinic

Milind Y. Desai, MD
Haslam Family Endowed Chair in Cardiovascular Medicine, Department of Cardiovascular Medicine, Heart and Vascular Institute, and Department of Diagnostic Radiology, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Address: Shailee Y. Shah, MD, Department of Internal Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; shahs10@ccf.org

Article PDF
Article PDF
Related Articles

Bicuspid aortic valve may initially be asymptomatic, but it is associated with progressive valvular and aortic abnormalities that can lead to chronic heart failure and sudden death. Regular monitoring is required with an eye toward surgery when indicated.

See related editorial

This article reviews inheritance patterns and conditions associated with bicuspid aortic valve. We discuss diagnosis, management, and monitoring, and offer surgical recommendations. Special guidance for dental procedures, pregnancy, and athletes is also provided.

A YOUNG MAN WITH PALPITATIONS AND A MURMUR

A 34-year-old man presented to an outpatient clinic with occasional palpitations over the past several months. He reported that he had been diagnosed with a murmur as a child but had received no further testing.

Physical examination at this time revealed a faint systolic crescendo-decrescendo murmur along the right sternal border without radiation to the carotid arteries or to the apex. Transthoracic echocardiography (TTE) showed a bicuspid aortic valve with fusion of the right and left coronary cusps, with no aortic valve stenosis or insufficiency. There was mild dilation of the aortic root, but the mid-ascending aorta could not be evaluated because of limited acoustic windows.

Is further diagnostic testing needed, and if so, what? May he participate in exertional physical activity? Does his newborn son need evaluation?

ABNORMALITIES OCCUR DURING EMBRYOGENESIS

Bicuspid aortic valve develops because of abnormal valvulogenesis. Adjacent cusps fail to separate from each other, resulting in only 2 cusps, with 1 usually larger than the other. Morphology varies according to which commissures are fused.1

Bicuspid aortic valve is associated with abnormalities in the coronary artery anatomy in about 2% of patients, including anomalous origins of the coronary arteries and upwardly displaced coronary ostia.2 Such features need to be considered before surgical intervention.

Bicuspid aortic valve can be found in 1% to 2% of the general population, with a male-to-female predominance of 3:1.1,3,4 It is one of the most common congenital cardiac malformations and is the leading congenital cause of aortic valve stenosis.1,3 However, routine screening of newborns for the condition is not recommended, and most cases are diagnosed incidentally.

GENETIC FACTORS PROMINENT

Bicuspid aortic valve is thought to be primarily inherited in an autosomal-dominant pattern, but there is evidence of genetic heterogeneity, and the pattern may be variable.5,6

No single gene responsible for bicuspid aortic valve has been identified. The condition may occur as a component of different pleiotropic genetic syndromes such as Loeys-Dietz, DiGeorge, and Marfan syndromes,7,8 as well as in patients with Turner syndrome and Williams syndrome.8–11 It also commonly coexists with other congenital heart diseases, including ventricular septal defect, isolated aortic arch obstruction, and patent ductus arteriosus.9

Studies have found a 15% rate of familial clustering.6,12 In a study of 142 patients with bicuspid aortic valve, 20% of first-degree relatives had some cardiac abnormality found by screening, of whom 68% had bicuspid aortic valve. Of these, 71% were newly detected abnormalities.13

CHARACTERISTIC CLICK AND MURMUR

Physical examination findings of a functionally normal bicuspid aortic valve include a systolic ejection click followed by an early peaking systolic murmur at the apex or left lower sternal border. With progression of aortic stenosis, the ejection murmur has a harsher sound, with later peaking, and the S2 sound diminishes or becomes inaudible.14 If aortic regurgitation is present, a diastolic decrescendo murmur is heard best at the left lower sternal border.

 

 

DISEASE PROGRESSION

Although bicuspid aortic valve is typically asymp­tomatic at first, it is commonly associated with progressive valvulopathy and thoracic aortic disease.1,3,4,15 It can lead to chronic heart failure and increase the risk of acute aortic syndromes and sudden cardiac death.15

Michelena et al16 studied 212 cases of asymp­tomatic bicuspid aortic valve. Although the survival rate 20 years after diagnosis was the same as for an age-matched cohort in the general population, the frequency of adverse cardiovascular events and surgical interventions was higher.

Aortic stenosis progresses rapidly

Aortic stenosis associated with a bicuspid aortic valve tends to affect younger patients and progress more rapidly than when associated with a tricuspid valve.17

In a study of 542 patients with congenital bicuspid aortic valve undergoing aortic valve replacement,3 75% had isolated aortic stenosis, 10% had aortic stenosis with some degree of aortic insufficiency, and 13% had isolated aortic insufficiency. Given the tendency of aortic stenosis to progress rapidly, early surgery is often pursued.17,18

Aneurysmal disease is common

The thoracic aorta is at increased risk of aneurysmal disease, coarctation, and dissection in patients with a bicuspid aortic valve.1,6,15

Michelena et al16 reported that in patients without an aneurysm at the time of bicuspid aortic valve diagnosis, the 25-year risk of aneurysm formation was approximately 26%. In patients with an aneurysm at the time of diagnosis, the 15-year risk of aortic surgery after the diagnosis of aneurysm was about 46% and the risk of aortic dissection after aneurysm diagnosis was 7%.15 Compared with the general population, the age-adjusted relative risk of aortic aneurysm in patients with bicuspid aortic valve was 86.2, and that of aortic dissection was 8.4. Although the absolute incidence of dissection is low in these patients, it is markedly higher than in the general population, particularly in older patients (age > 50) and those with an aneurysm at the time of diagnosis.15

The risk of infective endocarditis

Patients with bicuspid aortic valve are highly prone to infective endocarditis for reasons that remain poorly understood. The pathogens in most cases are staphylococci or viridans streptococci.19 Patients with infective endocarditis typically require emergency surgery. Complications including valvular abscess, myocardial abscess, and overt heart failure are common.19

Lamas and Eykyn20 studied 408 cases of native valve endocarditis; in 12.3%, the patient had a bicuspid aortic valve. In this subset, all were male, the mean age was 39 at diagnosis, 82% needed surgery, and the death rate was 14%.

Patients with bicuspid aortic valve do not routinely need antibiotics before dental and surgical procedures, but if they have had endocarditis in the past, they need antibiotics to prevent a recurrence.21

REGULAR MONITORING NEEDED

Because complications may be life-threatening, early detection of progressive disease by regular screening is critical. Echocardiographic evaluation of valvular function, ventricular dimensions and function, and diameter of the aortic root and ascending aorta should be performed in every patient with bicuspid aortic valve. If initial imaging is normal and there is no aortic dilation, imaging should be repeated every 5 to 10 years. If any abnormality is found, repeat imaging is needed every year.22

Transthoracic echocardiography
Figure 1. Transthoracic echocardiography, parasternal long-axis view, shows a dilated aortic root (AR) measuring 4.5 cm in a patient with bicuspid aortic valve (arrows). AA, ascending aorta; LA, left atrium; LV, left ventricle.

Two-dimensional transesophageal echocardiography
Figure 2. Two-dimensional transesophageal echocardiography demonstrates an anterior-posterior bicuspid aortic valve (opening phase, arrows). RA, right atrium; LA, left atrium; RV, right ventricle.

Magnetic resonance imaging (MRI) or computed tomographic (CT) angiography may be required to better assess the aorta for patients requiring a surgical intervention, or when aortic dimensions are not clearly visualized on TTE. MRI has 2 advantages over CT angiography: it poses no radiation risk, and it provides more information on left ventricular function and dimensions, in addition to valve assessment.23,24

No published study has compared MRI or CT angiography and transesophageal echocardiography (TEE), but in a study of 174 patients with dilated aortic root, combined TTE and TEE detected aortic valve morphology accurately in 98% of cases. As TEE is more invasive, it is not recommended for regular surveillance (Figures 1 and 2).25

FAMILY SCREENING RECOMMENDED

Close relatives should be evaluated for aortic valve and thoracic aortic disease.12,13,23,26

The American College of Cardiology (ACC) and the American Heart Association (AHA), backed by radiologic and cardiovascular associations, concur in recommending echocardiographic screening and routine screening of the thoracic aorta for aortic root dilation in first-degree relatives (ie, siblings, parents, and children) of patients with bicuspid aortic valve (class I recommendation).22,27,28

A comprehensive physical examination is recommended for family members in addition to TTE, with careful assessment of the aortic valve in short and long axes, and of the aortic root.14 If the aorta cannot be adequately evaluated with TTE, further assessment should be pursued with CT angiography or MRI.

 

 

EXERCISE RESTRICTIONS

The 2015 ACC/AHA guidelines for competitive athletes with cardiovascular abnormalities recommend annual screening with TTE or MRI angiography for athletes with bicuspid aortic valve and coexisting dilation of the ascending aorta (aortic diameter 40–42 mm in men and 36–39 mm in women) (class I recommendation, level of evidence C).29

Athletes with a bicuspid aortic valve and a normal aortic root and ascending aorta may participate in all competitive activities.29 However, those with a dilated aorta should avoid strenuous activities because of the increased risk of rupture.30 The ACC/AHA recommendations29 depend on the diameter of the ascending aorta and the nature of the sport:

  • For an aortic diameter 40 to 42 mm in men or 36 to 39 mm in women, and no features of connective tissue disease or familial thoracic ascending aortic syndrome, low- and moderate-intensity sports with a low likelihood of significant body contact may be considered; consider avoiding intense weight training (class IIb, level of evidence C)
  • For an aortic diameter 43 to 45 mm, low-intensity sports with a low likelihood of body contact may be considered (class IIb, level of evidence C)
  • For an aortic diameter greater than 43 mm in men or greater than 40 mm in women, sports involving body collision should be avoided (class III, level of evidence C)
  • For an aortic diameter greater than 45 mm, sports activities should be avoided (class III, level of evidence C).

PREGNANCY CONSIDERATIONS

Bicuspid aortic valve is associated with aortic dissection, mainly in the third trimester.31 Patients should ideally undergo echocardiographic screening before conception. The 2010 ACC/AHA guidelines for managing thoracic aortic disease recommend monthly or bimonthly echocardiography until delivery in pregnant women with a dilated thoracic aorta.22

Patients with bicuspid aortic valve and aortic root enlargement of more than 40 mm should have preconception counseling about surgery for aortic root replacement before becoming pregnant. If the diagnosis of enlarged aortic root is made during pregnancy, echocardiographic surveillance at 4- to 6-week intervals is indicated.32

SURGICAL MANAGEMENT

In the past, beta-blockers and angiotensin-converting enzyme inhibitors were recommended to minimize shear stress, with the goal of slowing progression of aortic dilation. However, evidence to support their use is inadequate.33,34

The only definitive treatment is surgery, with various procedures that lower the risk of death or dissection.24,35

The dimensions of the aortic root or ascending aorta should be examined vigilantly, according to the 2014 ACC/AHA guidelines27:

  • Repairing the aortic sinuses or replacing the ascending aorta is indicated if the diameter of the aortic sinuses or ascending aorta is greater than 5.5 cm (class I, level of evidence B)
  • Repairing the aortic sinuses or replacing the ascending aorta is reasonable if the diameter of the aortic sinuses or ascending aorta is greater than 5.0 cm and the patient has a risk factor for dissection such as a family history of aortic dissection or an increase in diameter of 0.5 cm or greater per year (class IIa, level of evidence C)
  • Replacement of the ascending aorta is reasonable if the diameter of the ascending aorta is greater than 4.5 cm and the patient is undergoing aortic valve surgery for severe aortic stenosis or regurgitation.

Valve repair or replacement

Aortic valve repair or replacement is sometimes done separately from aortic root repair.

The value of aortic valve repair is debatable, but a series of 728 patients at Cleveland Clinic showed a very low mortality rate (0.41%) and an annual reoperation rate of 2.6% during up to 15 years of follow-up.36

Aortic valve replacement is usually considered for patients with severe valve dysfunction, abnormal left ventricular dimensions, or symptoms. It is important to determine if the patient is a good surgical candidate and to refer early for surgical evaluation to avoid the higher risk of death associated with emergency surgery.36

Transcatheter aortic valve replacement has been studied in patients deemed to be at too high a risk for surgical replacement. Short- and intermediate-term outcomes have been good in these patients, but long-term data are lacking.37

Surveillance after surgery

The type of operation determines postoperative surveillance.

After isolated aortic valve repair or replacement, patients should continue with surveillance at least annually to monitor for progressive aortopathy, as they remain at increased risk of dissection or rupture after isolated valve surgery, especially if they had aortic insufficiency preoperatively.38

After definitive surgery with replacement or repair of the ascending aorta, no clear recommendations have been established for continued surveillance. However, it is reasonable to image these patients with either MRI or CT angiography 3 to 5 years after their surgery to monitor for anastomotic complications.

CASE QUESTIONS ANSWERED

Our patient should undergo repeat TTE in 1 year. He should also undergo CT angiography of the ascending aorta if it is not seen by TTE. He can participate in low-intensity sports but should avoid intense weight training. His parents, siblings, and children should be screened for bicuspid aortic valve or associated aortopathies.

Bicuspid aortic valve may initially be asymptomatic, but it is associated with progressive valvular and aortic abnormalities that can lead to chronic heart failure and sudden death. Regular monitoring is required with an eye toward surgery when indicated.

See related editorial

This article reviews inheritance patterns and conditions associated with bicuspid aortic valve. We discuss diagnosis, management, and monitoring, and offer surgical recommendations. Special guidance for dental procedures, pregnancy, and athletes is also provided.

A YOUNG MAN WITH PALPITATIONS AND A MURMUR

A 34-year-old man presented to an outpatient clinic with occasional palpitations over the past several months. He reported that he had been diagnosed with a murmur as a child but had received no further testing.

Physical examination at this time revealed a faint systolic crescendo-decrescendo murmur along the right sternal border without radiation to the carotid arteries or to the apex. Transthoracic echocardiography (TTE) showed a bicuspid aortic valve with fusion of the right and left coronary cusps, with no aortic valve stenosis or insufficiency. There was mild dilation of the aortic root, but the mid-ascending aorta could not be evaluated because of limited acoustic windows.

Is further diagnostic testing needed, and if so, what? May he participate in exertional physical activity? Does his newborn son need evaluation?

ABNORMALITIES OCCUR DURING EMBRYOGENESIS

Bicuspid aortic valve develops because of abnormal valvulogenesis. Adjacent cusps fail to separate from each other, resulting in only 2 cusps, with 1 usually larger than the other. Morphology varies according to which commissures are fused.1

Bicuspid aortic valve is associated with abnormalities in the coronary artery anatomy in about 2% of patients, including anomalous origins of the coronary arteries and upwardly displaced coronary ostia.2 Such features need to be considered before surgical intervention.

Bicuspid aortic valve can be found in 1% to 2% of the general population, with a male-to-female predominance of 3:1.1,3,4 It is one of the most common congenital cardiac malformations and is the leading congenital cause of aortic valve stenosis.1,3 However, routine screening of newborns for the condition is not recommended, and most cases are diagnosed incidentally.

GENETIC FACTORS PROMINENT

Bicuspid aortic valve is thought to be primarily inherited in an autosomal-dominant pattern, but there is evidence of genetic heterogeneity, and the pattern may be variable.5,6

No single gene responsible for bicuspid aortic valve has been identified. The condition may occur as a component of different pleiotropic genetic syndromes such as Loeys-Dietz, DiGeorge, and Marfan syndromes,7,8 as well as in patients with Turner syndrome and Williams syndrome.8–11 It also commonly coexists with other congenital heart diseases, including ventricular septal defect, isolated aortic arch obstruction, and patent ductus arteriosus.9

Studies have found a 15% rate of familial clustering.6,12 In a study of 142 patients with bicuspid aortic valve, 20% of first-degree relatives had some cardiac abnormality found by screening, of whom 68% had bicuspid aortic valve. Of these, 71% were newly detected abnormalities.13

CHARACTERISTIC CLICK AND MURMUR

Physical examination findings of a functionally normal bicuspid aortic valve include a systolic ejection click followed by an early peaking systolic murmur at the apex or left lower sternal border. With progression of aortic stenosis, the ejection murmur has a harsher sound, with later peaking, and the S2 sound diminishes or becomes inaudible.14 If aortic regurgitation is present, a diastolic decrescendo murmur is heard best at the left lower sternal border.

 

 

DISEASE PROGRESSION

Although bicuspid aortic valve is typically asymp­tomatic at first, it is commonly associated with progressive valvulopathy and thoracic aortic disease.1,3,4,15 It can lead to chronic heart failure and increase the risk of acute aortic syndromes and sudden cardiac death.15

Michelena et al16 studied 212 cases of asymp­tomatic bicuspid aortic valve. Although the survival rate 20 years after diagnosis was the same as for an age-matched cohort in the general population, the frequency of adverse cardiovascular events and surgical interventions was higher.

Aortic stenosis progresses rapidly

Aortic stenosis associated with a bicuspid aortic valve tends to affect younger patients and progress more rapidly than when associated with a tricuspid valve.17

In a study of 542 patients with congenital bicuspid aortic valve undergoing aortic valve replacement,3 75% had isolated aortic stenosis, 10% had aortic stenosis with some degree of aortic insufficiency, and 13% had isolated aortic insufficiency. Given the tendency of aortic stenosis to progress rapidly, early surgery is often pursued.17,18

Aneurysmal disease is common

The thoracic aorta is at increased risk of aneurysmal disease, coarctation, and dissection in patients with a bicuspid aortic valve.1,6,15

Michelena et al16 reported that in patients without an aneurysm at the time of bicuspid aortic valve diagnosis, the 25-year risk of aneurysm formation was approximately 26%. In patients with an aneurysm at the time of diagnosis, the 15-year risk of aortic surgery after the diagnosis of aneurysm was about 46% and the risk of aortic dissection after aneurysm diagnosis was 7%.15 Compared with the general population, the age-adjusted relative risk of aortic aneurysm in patients with bicuspid aortic valve was 86.2, and that of aortic dissection was 8.4. Although the absolute incidence of dissection is low in these patients, it is markedly higher than in the general population, particularly in older patients (age > 50) and those with an aneurysm at the time of diagnosis.15

The risk of infective endocarditis

Patients with bicuspid aortic valve are highly prone to infective endocarditis for reasons that remain poorly understood. The pathogens in most cases are staphylococci or viridans streptococci.19 Patients with infective endocarditis typically require emergency surgery. Complications including valvular abscess, myocardial abscess, and overt heart failure are common.19

Lamas and Eykyn20 studied 408 cases of native valve endocarditis; in 12.3%, the patient had a bicuspid aortic valve. In this subset, all were male, the mean age was 39 at diagnosis, 82% needed surgery, and the death rate was 14%.

Patients with bicuspid aortic valve do not routinely need antibiotics before dental and surgical procedures, but if they have had endocarditis in the past, they need antibiotics to prevent a recurrence.21

REGULAR MONITORING NEEDED

Because complications may be life-threatening, early detection of progressive disease by regular screening is critical. Echocardiographic evaluation of valvular function, ventricular dimensions and function, and diameter of the aortic root and ascending aorta should be performed in every patient with bicuspid aortic valve. If initial imaging is normal and there is no aortic dilation, imaging should be repeated every 5 to 10 years. If any abnormality is found, repeat imaging is needed every year.22

Transthoracic echocardiography
Figure 1. Transthoracic echocardiography, parasternal long-axis view, shows a dilated aortic root (AR) measuring 4.5 cm in a patient with bicuspid aortic valve (arrows). AA, ascending aorta; LA, left atrium; LV, left ventricle.

Two-dimensional transesophageal echocardiography
Figure 2. Two-dimensional transesophageal echocardiography demonstrates an anterior-posterior bicuspid aortic valve (opening phase, arrows). RA, right atrium; LA, left atrium; RV, right ventricle.

Magnetic resonance imaging (MRI) or computed tomographic (CT) angiography may be required to better assess the aorta for patients requiring a surgical intervention, or when aortic dimensions are not clearly visualized on TTE. MRI has 2 advantages over CT angiography: it poses no radiation risk, and it provides more information on left ventricular function and dimensions, in addition to valve assessment.23,24

No published study has compared MRI or CT angiography and transesophageal echocardiography (TEE), but in a study of 174 patients with dilated aortic root, combined TTE and TEE detected aortic valve morphology accurately in 98% of cases. As TEE is more invasive, it is not recommended for regular surveillance (Figures 1 and 2).25

FAMILY SCREENING RECOMMENDED

Close relatives should be evaluated for aortic valve and thoracic aortic disease.12,13,23,26

The American College of Cardiology (ACC) and the American Heart Association (AHA), backed by radiologic and cardiovascular associations, concur in recommending echocardiographic screening and routine screening of the thoracic aorta for aortic root dilation in first-degree relatives (ie, siblings, parents, and children) of patients with bicuspid aortic valve (class I recommendation).22,27,28

A comprehensive physical examination is recommended for family members in addition to TTE, with careful assessment of the aortic valve in short and long axes, and of the aortic root.14 If the aorta cannot be adequately evaluated with TTE, further assessment should be pursued with CT angiography or MRI.

 

 

EXERCISE RESTRICTIONS

The 2015 ACC/AHA guidelines for competitive athletes with cardiovascular abnormalities recommend annual screening with TTE or MRI angiography for athletes with bicuspid aortic valve and coexisting dilation of the ascending aorta (aortic diameter 40–42 mm in men and 36–39 mm in women) (class I recommendation, level of evidence C).29

Athletes with a bicuspid aortic valve and a normal aortic root and ascending aorta may participate in all competitive activities.29 However, those with a dilated aorta should avoid strenuous activities because of the increased risk of rupture.30 The ACC/AHA recommendations29 depend on the diameter of the ascending aorta and the nature of the sport:

  • For an aortic diameter 40 to 42 mm in men or 36 to 39 mm in women, and no features of connective tissue disease or familial thoracic ascending aortic syndrome, low- and moderate-intensity sports with a low likelihood of significant body contact may be considered; consider avoiding intense weight training (class IIb, level of evidence C)
  • For an aortic diameter 43 to 45 mm, low-intensity sports with a low likelihood of body contact may be considered (class IIb, level of evidence C)
  • For an aortic diameter greater than 43 mm in men or greater than 40 mm in women, sports involving body collision should be avoided (class III, level of evidence C)
  • For an aortic diameter greater than 45 mm, sports activities should be avoided (class III, level of evidence C).

PREGNANCY CONSIDERATIONS

Bicuspid aortic valve is associated with aortic dissection, mainly in the third trimester.31 Patients should ideally undergo echocardiographic screening before conception. The 2010 ACC/AHA guidelines for managing thoracic aortic disease recommend monthly or bimonthly echocardiography until delivery in pregnant women with a dilated thoracic aorta.22

Patients with bicuspid aortic valve and aortic root enlargement of more than 40 mm should have preconception counseling about surgery for aortic root replacement before becoming pregnant. If the diagnosis of enlarged aortic root is made during pregnancy, echocardiographic surveillance at 4- to 6-week intervals is indicated.32

SURGICAL MANAGEMENT

In the past, beta-blockers and angiotensin-converting enzyme inhibitors were recommended to minimize shear stress, with the goal of slowing progression of aortic dilation. However, evidence to support their use is inadequate.33,34

The only definitive treatment is surgery, with various procedures that lower the risk of death or dissection.24,35

The dimensions of the aortic root or ascending aorta should be examined vigilantly, according to the 2014 ACC/AHA guidelines27:

  • Repairing the aortic sinuses or replacing the ascending aorta is indicated if the diameter of the aortic sinuses or ascending aorta is greater than 5.5 cm (class I, level of evidence B)
  • Repairing the aortic sinuses or replacing the ascending aorta is reasonable if the diameter of the aortic sinuses or ascending aorta is greater than 5.0 cm and the patient has a risk factor for dissection such as a family history of aortic dissection or an increase in diameter of 0.5 cm or greater per year (class IIa, level of evidence C)
  • Replacement of the ascending aorta is reasonable if the diameter of the ascending aorta is greater than 4.5 cm and the patient is undergoing aortic valve surgery for severe aortic stenosis or regurgitation.

Valve repair or replacement

Aortic valve repair or replacement is sometimes done separately from aortic root repair.

The value of aortic valve repair is debatable, but a series of 728 patients at Cleveland Clinic showed a very low mortality rate (0.41%) and an annual reoperation rate of 2.6% during up to 15 years of follow-up.36

Aortic valve replacement is usually considered for patients with severe valve dysfunction, abnormal left ventricular dimensions, or symptoms. It is important to determine if the patient is a good surgical candidate and to refer early for surgical evaluation to avoid the higher risk of death associated with emergency surgery.36

Transcatheter aortic valve replacement has been studied in patients deemed to be at too high a risk for surgical replacement. Short- and intermediate-term outcomes have been good in these patients, but long-term data are lacking.37

Surveillance after surgery

The type of operation determines postoperative surveillance.

After isolated aortic valve repair or replacement, patients should continue with surveillance at least annually to monitor for progressive aortopathy, as they remain at increased risk of dissection or rupture after isolated valve surgery, especially if they had aortic insufficiency preoperatively.38

After definitive surgery with replacement or repair of the ascending aorta, no clear recommendations have been established for continued surveillance. However, it is reasonable to image these patients with either MRI or CT angiography 3 to 5 years after their surgery to monitor for anastomotic complications.

CASE QUESTIONS ANSWERED

Our patient should undergo repeat TTE in 1 year. He should also undergo CT angiography of the ascending aorta if it is not seen by TTE. He can participate in low-intensity sports but should avoid intense weight training. His parents, siblings, and children should be screened for bicuspid aortic valve or associated aortopathies.

References
  1. Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am J Cardiol 1970; 26(1):72–83. pmid:5427836
  2. Michalowska IM, Hryniewiecki T, Kwiatek P, Stoklosa P, Swoboda-Rydz U, Szymanski P. Coronary artery variants and anomalies in patients with bicuspid aortic valve. J Thorac Imaging 2016; 31(3):156–162. doi:10.1097/RTI.0000000000000205
  3. Sabet HY, Edwards WD, Tazelaar HD, Daly RC. Congenitally bicuspid aortic valves: a surgical pathology study of 542 cases (1991 through 1996) and a literature review of 2,715 additional cases. Mayo Clin Proc 1999; 74(1):14–26. doi:10.4065/74.1.14
  4. Tutar E, Ekici F, Atalay S, Nacar N. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. Am Heart J 2005; 150(3):513–515. doi:10.1016/j.ahj.2004.10.036
  5. Benson DW. The genetics of congenital heart disease: a point in the revolution. Cardiol Clin 2002; 20(3):385–394. pmid:12371007
  6. Emanuel R, Withers R, O’Brien K, Ross P, Feizi O. Congenitally bicuspid aortic valves. Clinicogenetic study of 41 families. Br Heart J 1978; 40(12):1402–1407. pmid:737099
  7. Giusti B, Sticchi E, De Cario R, Magi A, Nistri S, Pepe G. Genetic bases of bicuspid aortic valve: the contribution of traditional and high-throughput sequencing approaches on research and diagnosis. Front Physiol 2017; 8:612. doi:10.3389/fphys.2017.00612
  8. Sachdev V, Matura LA, Sidenko S, et al. Aortic valve disease in Turner syndrome. J Am Coll Cardiol 2008; 51(19):1904–1909. doi:10.1016/j.jacc.2008.02.035
  9. Duran AC, Frescura C, Sans-Coma V, Angelini A, Basso C, Thiene G. Bicuspid aortic valves in hearts with other congenital heart disease. J Heart Valve Dis 1995; 4(6):581–590. pmid:8611973
  10. De Rubens Figueroa J, Rodríguez LM, Hach JL, Del Castillo Ruíz V, Martínez HO. Cardiovascular spectrum in Williams-Beuren syndrome: the Mexican experience in 40 patients. Tex Heart Inst J 2008; 35(3):279–285. pmid:18941598
  11. Yuan SM, Jing H. The bicuspid aortic valve and related disorders. Sao Paulo Med J 2010; 128(5):296–301. pmid:21181071
  12. Cripe L, Andelfinger G, Martin LJ, Shooner K, Benson DW. Bicuspid aortic valve is heritable. J Am Coll Cardiol 2004; 44(1):138–143. doi:10.1016/j.jacc.2004.03.050
  13. Kerstjens-Frederikse WS, Sarvaas GJ, Ruiter JS, et al. Left ventricular outflow tract obstruction: should cardiac screening be offered to first-degree relatives? Heart 2011; 97(15):1228–1232. doi:10.1136/hrt.2010.211433
  14. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol 2010; 55(25):2789–2800. doi:10.1016/j.jacc.2009.12.068
  15. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011; 306(10):1104–1112.
  16. Michelena HI, Desjardins VA, Avierinos JF, et al. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation 2008; 117(21):2776–2784. doi:10.1161/CIRCULATIONAHA.107.740878
  17. Beppu S, Suzuki S, Matsuda H, Ohmori F, Nagata S, Miyatake K. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valves. Am J Cardiol 1993; 71(4):322–327. pmid:8427176
  18. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005; 111(7):920–925. doi:10.1161/01.CIR.0000155623.48408.C5
  19. Yener N, Oktar GL, Erer D, Yardimci MM, Yener A. Bicuspid aortic valve. Ann Thorac Cardiovasc Surg 2002; 8(5):264–267. pmid:12472407
  20. Lamas CC, Eykyn SJ. Bicuspid aortic valve—a silent danger: analysis of 50 cases of infective endocarditis. Clin Infect Dis 2000; 30(2):336–341. doi:10.1086/313646
  21. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation 2007; 116(15):1736–1754. doi:10.1161/CIRCULATIONAHA.106.183095
  22. Hiratzka L, Bakris G, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. Circulation 2010; 121(13):e266–e369. doi:10.1161/CIR.0b013e3181d4739e
  23. Chun EJ, Choi SI, Lim C, et al. Aortic stenosis: evaluation with multidetector CT angiography and MR imaging. Korean J Radiol 2008; 9(5):439–448. doi:10.3348/kjr.2008.9.5.439
  24. Kiefer TL, Wang A, Hughes GC, Bashore TM. Management of patients with bicuspid aortic valve disease. Curr Treat Options Cardiovasc Med 2011; 13(6):489–505. doi:10.1007/s11936-011-0152-7
  25. Alegret JM, Palazon O, Duran I, Vernis JM. Aortic valve morphology definition with transthoracic combined with transesophageal echocardiography in a population with high prevalence of bicuspid aortic valve. Int J Cardiovasc Imaging 2005; 21(2-3):213–217. doi:10.1007/s10554-004-3901-9
  26. Biner S, Rafique AM, Ray I, Cuk O, Siegel RJ, Tolstrup K. Aortopathy is prevalent in relatives of bicuspid aortic valve patients. J Am Coll Cardiol 2009; 53(24):2288–2295. doi:10.1016/j.jacc.2009.03.027
  27. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Thorac Cardiovasc Surg 2014; 148(1):e1-e132. doi:10.1016/j.jtcvs.2014.05.014
  28. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. J Am Coll Cardiol 2008; 52(23):e143–e263. doi:10.1016/j.jacc.2008.10.001
  29. Braverman AC, Harris KM, Kovacs RJ, Maron BJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 7: aortic diseases, including Marfan syndrome. Circulation 2015; 132(22):e303–e309. doi:10.1161/CIR.0000000000000243
  30. De Mozzi P, Longo UG, Galanti G, Maffulli N. Bicuspid aortic valve: a literature review and its impact on sport activity. Br Med Bull 2008; 85:63–85. doi:10.1093/bmb/ldn002
  31. Thorne SA. Pregnancy in heart disease. Heart 2004; 90(4):450–456. pmid:15020530
  32. Immer FF, Bansi AG, Immer-Bansi AS, et al. Aortic dissection in pregnancy: analysis of risk factors and outcome. Ann Thorac Surg 2003; 76(1):309–314. pmid:12842575
  33. Allen BD, Markl M, Barker AJ, et al. Influence of beta-blocker therapy on aortic blood flow in patients with bicuspid aortic valve. Int J Cardiovasc Imaging 2016; 32(4):621–628. doi:10.1007/s10554-015-0819-3
  34. Ohnemus D, Oster ME, Gatlin S, Jokhadar M, Mahle WT. The effect of angiotensin-converting enzyme inhibitors on the rate of ascending aorta dilation in patients with bicuspid aortic valve. Congenit Heart Dis 2015; 10(1):E1–E5. doi:10.1111/chd.12184
  35. Masri A, Kalahasti V, Alkharabsheh S, et al. Characteristics and long-term outcomes of contemporary patients with bicuspid aortic valves. J Thorac Cardiovasc Surg 2016; 151(6):1650–1659.e1. doi:10.1016/j.jtcvs.2015.12.019
  36. Svensson LG, Al Kindi AH, Vivacqua A, et al. Long-term durability of bicuspid aortic valve repair. Ann Thorac Surg 2014; 97(5):1539–1548. doi:10.1016/j.athoracsur.2013.11.036
  37. Mylotte D, Lefevre T, Sondergaard L, et al. Transcatheter aortic valve replacement in bicuspid aortic valve disease. J Am Coll Cardiol 2014; 64(22):2330–2339. doi:10.1016/j.jacc.2014.09.039
  38. Girdauskas E, Disha K, Raisin HH, Secknus MA, Borger MA, Kuntze T. Risk of late aortic events after an isolated aortic valve replacement for bicuspid aortic valve stenosis with concomitant ascending aortic dilation. Eur J Cardiothorac Surg 2012; 42(5):832–838. doi:10.1093/ejcts/ezs137
References
  1. Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am J Cardiol 1970; 26(1):72–83. pmid:5427836
  2. Michalowska IM, Hryniewiecki T, Kwiatek P, Stoklosa P, Swoboda-Rydz U, Szymanski P. Coronary artery variants and anomalies in patients with bicuspid aortic valve. J Thorac Imaging 2016; 31(3):156–162. doi:10.1097/RTI.0000000000000205
  3. Sabet HY, Edwards WD, Tazelaar HD, Daly RC. Congenitally bicuspid aortic valves: a surgical pathology study of 542 cases (1991 through 1996) and a literature review of 2,715 additional cases. Mayo Clin Proc 1999; 74(1):14–26. doi:10.4065/74.1.14
  4. Tutar E, Ekici F, Atalay S, Nacar N. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. Am Heart J 2005; 150(3):513–515. doi:10.1016/j.ahj.2004.10.036
  5. Benson DW. The genetics of congenital heart disease: a point in the revolution. Cardiol Clin 2002; 20(3):385–394. pmid:12371007
  6. Emanuel R, Withers R, O’Brien K, Ross P, Feizi O. Congenitally bicuspid aortic valves. Clinicogenetic study of 41 families. Br Heart J 1978; 40(12):1402–1407. pmid:737099
  7. Giusti B, Sticchi E, De Cario R, Magi A, Nistri S, Pepe G. Genetic bases of bicuspid aortic valve: the contribution of traditional and high-throughput sequencing approaches on research and diagnosis. Front Physiol 2017; 8:612. doi:10.3389/fphys.2017.00612
  8. Sachdev V, Matura LA, Sidenko S, et al. Aortic valve disease in Turner syndrome. J Am Coll Cardiol 2008; 51(19):1904–1909. doi:10.1016/j.jacc.2008.02.035
  9. Duran AC, Frescura C, Sans-Coma V, Angelini A, Basso C, Thiene G. Bicuspid aortic valves in hearts with other congenital heart disease. J Heart Valve Dis 1995; 4(6):581–590. pmid:8611973
  10. De Rubens Figueroa J, Rodríguez LM, Hach JL, Del Castillo Ruíz V, Martínez HO. Cardiovascular spectrum in Williams-Beuren syndrome: the Mexican experience in 40 patients. Tex Heart Inst J 2008; 35(3):279–285. pmid:18941598
  11. Yuan SM, Jing H. The bicuspid aortic valve and related disorders. Sao Paulo Med J 2010; 128(5):296–301. pmid:21181071
  12. Cripe L, Andelfinger G, Martin LJ, Shooner K, Benson DW. Bicuspid aortic valve is heritable. J Am Coll Cardiol 2004; 44(1):138–143. doi:10.1016/j.jacc.2004.03.050
  13. Kerstjens-Frederikse WS, Sarvaas GJ, Ruiter JS, et al. Left ventricular outflow tract obstruction: should cardiac screening be offered to first-degree relatives? Heart 2011; 97(15):1228–1232. doi:10.1136/hrt.2010.211433
  14. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol 2010; 55(25):2789–2800. doi:10.1016/j.jacc.2009.12.068
  15. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011; 306(10):1104–1112.
  16. Michelena HI, Desjardins VA, Avierinos JF, et al. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation 2008; 117(21):2776–2784. doi:10.1161/CIRCULATIONAHA.107.740878
  17. Beppu S, Suzuki S, Matsuda H, Ohmori F, Nagata S, Miyatake K. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valves. Am J Cardiol 1993; 71(4):322–327. pmid:8427176
  18. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005; 111(7):920–925. doi:10.1161/01.CIR.0000155623.48408.C5
  19. Yener N, Oktar GL, Erer D, Yardimci MM, Yener A. Bicuspid aortic valve. Ann Thorac Cardiovasc Surg 2002; 8(5):264–267. pmid:12472407
  20. Lamas CC, Eykyn SJ. Bicuspid aortic valve—a silent danger: analysis of 50 cases of infective endocarditis. Clin Infect Dis 2000; 30(2):336–341. doi:10.1086/313646
  21. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation 2007; 116(15):1736–1754. doi:10.1161/CIRCULATIONAHA.106.183095
  22. Hiratzka L, Bakris G, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. Circulation 2010; 121(13):e266–e369. doi:10.1161/CIR.0b013e3181d4739e
  23. Chun EJ, Choi SI, Lim C, et al. Aortic stenosis: evaluation with multidetector CT angiography and MR imaging. Korean J Radiol 2008; 9(5):439–448. doi:10.3348/kjr.2008.9.5.439
  24. Kiefer TL, Wang A, Hughes GC, Bashore TM. Management of patients with bicuspid aortic valve disease. Curr Treat Options Cardiovasc Med 2011; 13(6):489–505. doi:10.1007/s11936-011-0152-7
  25. Alegret JM, Palazon O, Duran I, Vernis JM. Aortic valve morphology definition with transthoracic combined with transesophageal echocardiography in a population with high prevalence of bicuspid aortic valve. Int J Cardiovasc Imaging 2005; 21(2-3):213–217. doi:10.1007/s10554-004-3901-9
  26. Biner S, Rafique AM, Ray I, Cuk O, Siegel RJ, Tolstrup K. Aortopathy is prevalent in relatives of bicuspid aortic valve patients. J Am Coll Cardiol 2009; 53(24):2288–2295. doi:10.1016/j.jacc.2009.03.027
  27. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Thorac Cardiovasc Surg 2014; 148(1):e1-e132. doi:10.1016/j.jtcvs.2014.05.014
  28. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. J Am Coll Cardiol 2008; 52(23):e143–e263. doi:10.1016/j.jacc.2008.10.001
  29. Braverman AC, Harris KM, Kovacs RJ, Maron BJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 7: aortic diseases, including Marfan syndrome. Circulation 2015; 132(22):e303–e309. doi:10.1161/CIR.0000000000000243
  30. De Mozzi P, Longo UG, Galanti G, Maffulli N. Bicuspid aortic valve: a literature review and its impact on sport activity. Br Med Bull 2008; 85:63–85. doi:10.1093/bmb/ldn002
  31. Thorne SA. Pregnancy in heart disease. Heart 2004; 90(4):450–456. pmid:15020530
  32. Immer FF, Bansi AG, Immer-Bansi AS, et al. Aortic dissection in pregnancy: analysis of risk factors and outcome. Ann Thorac Surg 2003; 76(1):309–314. pmid:12842575
  33. Allen BD, Markl M, Barker AJ, et al. Influence of beta-blocker therapy on aortic blood flow in patients with bicuspid aortic valve. Int J Cardiovasc Imaging 2016; 32(4):621–628. doi:10.1007/s10554-015-0819-3
  34. Ohnemus D, Oster ME, Gatlin S, Jokhadar M, Mahle WT. The effect of angiotensin-converting enzyme inhibitors on the rate of ascending aorta dilation in patients with bicuspid aortic valve. Congenit Heart Dis 2015; 10(1):E1–E5. doi:10.1111/chd.12184
  35. Masri A, Kalahasti V, Alkharabsheh S, et al. Characteristics and long-term outcomes of contemporary patients with bicuspid aortic valves. J Thorac Cardiovasc Surg 2016; 151(6):1650–1659.e1. doi:10.1016/j.jtcvs.2015.12.019
  36. Svensson LG, Al Kindi AH, Vivacqua A, et al. Long-term durability of bicuspid aortic valve repair. Ann Thorac Surg 2014; 97(5):1539–1548. doi:10.1016/j.athoracsur.2013.11.036
  37. Mylotte D, Lefevre T, Sondergaard L, et al. Transcatheter aortic valve replacement in bicuspid aortic valve disease. J Am Coll Cardiol 2014; 64(22):2330–2339. doi:10.1016/j.jacc.2014.09.039
  38. Girdauskas E, Disha K, Raisin HH, Secknus MA, Borger MA, Kuntze T. Risk of late aortic events after an isolated aortic valve replacement for bicuspid aortic valve stenosis with concomitant ascending aortic dilation. Eur J Cardiothorac Surg 2012; 42(5):832–838. doi:10.1093/ejcts/ezs137
Issue
Cleveland Clinic Journal of Medicine - 85(10)
Issue
Cleveland Clinic Journal of Medicine - 85(10)
Page Number
779-784
Page Number
779-784
Publications
Publications
Topics
Article Type
Display Headline
Bicuspid aortic valve: Basics and beyond
Display Headline
Bicuspid aortic valve: Basics and beyond
Legacy Keywords
bicuspid aortic valve, BAV, aorta, aortopathy, echocardiography, stenosis, aneurysm, Loeys-Dietz syndrome, Marfan syndrome, DiGeorge syndrome, Turner syndrome, Williams syndrome, infective endocarditis, Shailee Shah, Andrew Higgins, Milind Desai
Legacy Keywords
bicuspid aortic valve, BAV, aorta, aortopathy, echocardiography, stenosis, aneurysm, Loeys-Dietz syndrome, Marfan syndrome, DiGeorge syndrome, Turner syndrome, Williams syndrome, infective endocarditis, Shailee Shah, Andrew Higgins, Milind Desai
Sections
Inside the Article

KEY POINTS

  • Associated aortopathies such as aortic root dilation, aneurysm, dissection, and coarctation may initially be asymptomatic.
  • Regular surveillance with transthoracic echocardiography (TTE) is required.
  • Transesophageal echocardiography should be performed if TTE does not clearly show the aorta and aortic root. Magnetic resonance imaging or computed tomographic angiography may also be needed to measure the aortic root and ascending thoracic aorta.
  • If initial imaging is normal and there is no aortic dilation, repeat imaging should be done every 5 to 10 years. If any abnormality is found, annual surveillance is needed.
  • Women with a bicuspid aortic valve who are contemplating pregnancy should undergo echocardiography first, and some may need to undergo surgery.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 09/26/2018 - 11:30
Un-Gate On Date
Wed, 09/26/2018 - 11:30
Use ProPublica
CFC Schedule Remove Status
Wed, 09/26/2018 - 11:30
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

In reply: Aortic aneurysm: Fluoroquinolones, genetic counseling

Article Type
Changed
Tue, 09/04/2018 - 09:17
Display Headline
In reply: Aortic aneurysm: Fluoroquinolones, genetic counseling

In Reply: We thank Drs. Goldstein and Mascitelli for their comments regarding fluoroquinolones and thoracic aortic aneurysms. We acknowledge that fluoroquinolones (particularly ciprofloxacin) have been associated with a risk of aortic aneurysm and dissection based on large observational studies from Taiwan, Canada, and Sweden. Although all of the studies have shown an association between ciprofloxacin and aortic aneurysm, the causative role is not well established. In addition, the numbers of events were very small in these large cohorts of patients. In our large tertiary care practice at Cleveland Clinic, we have very few patients with aortic aneurysm or dissection who have used fluoroquinolones.

We recognize the association; however, our paper was intended to emphasize the more common causes and treatment options that primary care physicians are likely to encounter in routine practice.

We also thank Drs. Ayoubieh and MacCarrick for their comments about genetic counseling. We agree that genetic counseling is important, as is a detailed physical examination for subtle features of genetically mediated aortic aneurysm. In fact, we incorporate the physical examination when patients are seen at our aortic center so as to recognize the physical features. We do routinely recommend screening of first-degree relatives even without significant family history on an individual basis and make appropriate referrals for other conditions that can be seen in these patients. Our article, however, is primarily intended to emphasize the importance of referring these patients for more-focused care at a specialized center, where we incorporate all of the suggestions that were made.

Article PDF
Author and Disclosure Information

Vidyasagar Kalahasti, MD
Cleveland Clinic

Frank Cikach, MD
Cleveland Clinic

Milind Y. Desai, MD, FACC, FAHA, FESC
Cleveland Clinic

Eric E. Roselli, MD, FACS
Cleveland Clinic

Issue
Cleveland Clinic Journal of Medicine - 85(9)
Publications
Topics
Page Number
661-662
Legacy Keywords
thoracic aortic aneurysm, fluroquinolones, genetic counseling, Vidyasagar Kalahasti, Frank Cikach, Milind Desai, Eric Roselli
Sections
Author and Disclosure Information

Vidyasagar Kalahasti, MD
Cleveland Clinic

Frank Cikach, MD
Cleveland Clinic

Milind Y. Desai, MD, FACC, FAHA, FESC
Cleveland Clinic

Eric E. Roselli, MD, FACS
Cleveland Clinic

Author and Disclosure Information

Vidyasagar Kalahasti, MD
Cleveland Clinic

Frank Cikach, MD
Cleveland Clinic

Milind Y. Desai, MD, FACC, FAHA, FESC
Cleveland Clinic

Eric E. Roselli, MD, FACS
Cleveland Clinic

Article PDF
Article PDF
Related Articles

In Reply: We thank Drs. Goldstein and Mascitelli for their comments regarding fluoroquinolones and thoracic aortic aneurysms. We acknowledge that fluoroquinolones (particularly ciprofloxacin) have been associated with a risk of aortic aneurysm and dissection based on large observational studies from Taiwan, Canada, and Sweden. Although all of the studies have shown an association between ciprofloxacin and aortic aneurysm, the causative role is not well established. In addition, the numbers of events were very small in these large cohorts of patients. In our large tertiary care practice at Cleveland Clinic, we have very few patients with aortic aneurysm or dissection who have used fluoroquinolones.

We recognize the association; however, our paper was intended to emphasize the more common causes and treatment options that primary care physicians are likely to encounter in routine practice.

We also thank Drs. Ayoubieh and MacCarrick for their comments about genetic counseling. We agree that genetic counseling is important, as is a detailed physical examination for subtle features of genetically mediated aortic aneurysm. In fact, we incorporate the physical examination when patients are seen at our aortic center so as to recognize the physical features. We do routinely recommend screening of first-degree relatives even without significant family history on an individual basis and make appropriate referrals for other conditions that can be seen in these patients. Our article, however, is primarily intended to emphasize the importance of referring these patients for more-focused care at a specialized center, where we incorporate all of the suggestions that were made.

In Reply: We thank Drs. Goldstein and Mascitelli for their comments regarding fluoroquinolones and thoracic aortic aneurysms. We acknowledge that fluoroquinolones (particularly ciprofloxacin) have been associated with a risk of aortic aneurysm and dissection based on large observational studies from Taiwan, Canada, and Sweden. Although all of the studies have shown an association between ciprofloxacin and aortic aneurysm, the causative role is not well established. In addition, the numbers of events were very small in these large cohorts of patients. In our large tertiary care practice at Cleveland Clinic, we have very few patients with aortic aneurysm or dissection who have used fluoroquinolones.

We recognize the association; however, our paper was intended to emphasize the more common causes and treatment options that primary care physicians are likely to encounter in routine practice.

We also thank Drs. Ayoubieh and MacCarrick for their comments about genetic counseling. We agree that genetic counseling is important, as is a detailed physical examination for subtle features of genetically mediated aortic aneurysm. In fact, we incorporate the physical examination when patients are seen at our aortic center so as to recognize the physical features. We do routinely recommend screening of first-degree relatives even without significant family history on an individual basis and make appropriate referrals for other conditions that can be seen in these patients. Our article, however, is primarily intended to emphasize the importance of referring these patients for more-focused care at a specialized center, where we incorporate all of the suggestions that were made.

Issue
Cleveland Clinic Journal of Medicine - 85(9)
Issue
Cleveland Clinic Journal of Medicine - 85(9)
Page Number
661-662
Page Number
661-662
Publications
Publications
Topics
Article Type
Display Headline
In reply: Aortic aneurysm: Fluoroquinolones, genetic counseling
Display Headline
In reply: Aortic aneurysm: Fluoroquinolones, genetic counseling
Legacy Keywords
thoracic aortic aneurysm, fluroquinolones, genetic counseling, Vidyasagar Kalahasti, Frank Cikach, Milind Desai, Eric Roselli
Legacy Keywords
thoracic aortic aneurysm, fluroquinolones, genetic counseling, Vidyasagar Kalahasti, Frank Cikach, Milind Desai, Eric Roselli
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 08/28/2018 - 15:15
Un-Gate On Date
Tue, 08/28/2018 - 15:15
Use ProPublica
CFC Schedule Remove Status
Tue, 08/28/2018 - 15:15
Article PDF Media

Thoracic aortic aneurysm: How to counsel, when to refer

Article Type
Changed
Mon, 06/03/2019 - 08:47
Display Headline
Thoracic aortic aneurysm: How to counsel, when to refer

Thoracic aortic aneurysm (TAA) needs to be detected, monitored, and managed in a timely manner to prevent a serious consequence such as acute dissection or rupture. But only about 5% of patients experience symptoms before an acute event occurs, and for the other 95% the first “symptom” is often death.1 Most cases are detected either incidentally with echocardiography, computed tomography (CT), or magnetic resonance imaging (MRI) during workup for another condition. Patients may also be diagnosed during workup of a murmur or after a family member is found to have an aneurysm. Therefore, its true incidence is difficult to determine.2

With these facts in mind, how would you manage the following 2 cases?

Case 1: Bicuspid aortic valve, ascending aortic aneurysm

A 45-year-old man with stage 1 hypertension presents for evaluation of a bicuspid aortic valve and ascending aortic aneurysm. He has several first-degree relatives with similar conditions, and his brother recently underwent elective aortic repair. At the urging of his primary care physician, he underwent screening echocardiography, which demonstrated a “dilated root and ascending aorta” 4.6 cm in diameter. He presents today to discuss management options and how the aneurysm could affect his everyday life.

Case 2: Marfan syndrome in a young woman

A 24-year-old woman with Marfan syndrome diagnosed in adolescence presents for annual follow-up. She has many family members with the same condition, and several have undergone prophylactic aortic root repair. Her aortic root has been monitored annually for progression of dilation, and today it is 4.6 cm in diameter, a 3-mm increase from the last measurement. She has grade 2+ aortic insufficiency (on a scale of 1+ to 4+) based on echocardiography, but she has no symptoms. She is curious about what size her aortic root will need to reach for surgery to be considered.

LIKELY UNDERDETECTED

TAA is being detected more often than in the past thanks to better detection methods and heightened awareness among physicians and patients. While an incidence rate of 10.4 per 100,000 patient-years is often cited,3 this figure likely underestimates the true incidence of this clinically silent condition. The most robust data come from studies based on in-hospital diagnostic codes coupled with data from autopsies for out-of-hospital deaths.

Olsson et al,4 in a 2016 study in Sweden, found the incidence of TAA and aortic dissection to be 16.3 per 100,000 per year for men and 9.1 per 100,000 per year for women.

Clouse et al5 reported the incidence of thoracic aortic dissection as 3.5 per 100,000 patient-years, and the same figure for thoracic aortic rupture. 

Aneurysmal disease accounts for 52,000 deaths per year in the United States, making it the 19th most common cause of death.6 These figures are likely lower than the true mortality rate for this condition, given that aortic dissection is often mistaken for acute myocardial infarction or other acute event if an autopsy is not done to confirm the cause of death.7

RISK FACTORS FOR THORACIC AORTIC ANEURYSM

Risk factors for TAA include genetic conditions that lead to aortic medial weakness or destruction such as Loeys-Dietz syndrome and Marfan syndrome.2 In addition, family history is important even in the absence of known genetic mutations. Other risk factors include conditions that increase aortic wall stress, such as hypertension, cocaine abuse, extreme weightlifting, trauma, and aortic coarctation.2

DIAMETER INCREASES WITH AGE, BODY SURFACE AREA

Figure 1.
Figure 1.
The thoracic aorta consists of the root and the ascending, arch, and descending segments (Figure 1); the abdominal aorta consists of the suprarenal and infrarenal segments.8,9 These divisions are useful, as aneurysmal disease can be confined to specific locations along the length of the vessel, and the location can affect the clinical presentation and management decisions and lend insight into the pathogenesis.

Normal dimensions for the aortic segments differ depending on age, sex, and body surface area.8,44,45 The size of the aortic root may also vary depending on how it is measured, due to the root’s trefoil shape. Measured sinus to sinus, the root is larger than when measured sinus to commissure on CT angiography or cardiac MRI. It is also larger when measured leading edge to leading edge than inner edge to inner edge on echocardiography.10

TAA is defined as an aortic diameter at least 50% greater than the upper limit of normal.8 

Aortic diameters: Upper limits of normal
The aorta increases in diameter by 0.7 to 1.9 mm per year if not dilated, and larger-diameter aortas grow faster.11 In addition, men have a larger aortic diameter than women.10 Size-based criteria and indices are useful for defining and monitoring aneurysmal progression, since larger patients tend to have a larger aorta.10  Table 1 lists upper limits of normal values for the ascending and descending aorta by age, sex, and body surface area obtained by Wolak et al in a study using noncontrast CT.10

Geometric changes in the curvature of the ascending aorta, aortic arch, and descending thoracic aorta can occur as the result of hypertension, atherosclerosis, or connective tissue disease. 

 

 

HOW IS TAA DIAGNOSED?

Table 2: Common causes of thoracic aortic aneurysm
TAA is asymptomatic in most patients and is usually detected on imaging. However, it should be actively looked for in patients who have a family history of Marfan, Loeys-Dietz, or Ehlers-Danlos syndrome or a family history of aortic aneurysm or dissection (not necessarily in a first-degree relative, but more significant in a first-degree relative or in multiple family members across generations), and in patients with a bicuspid aortic valve or autoimmune disease such as Takayasu or giant cell arteritis (Table 2). Table 3 lists the common genetic disorders with their associated mutations and clinical features.

Table 3: Inherited connective tissue diseases and thoracic aortic aneurysm
Some patients present with chest pain that may be related to local compression due to the aorta’s large size. Hoarseness, dysphagia, or chronic cough may be a presenting symptom, particularly in patients with descending aortic aneurysm or congenital aortic anomaly.

Table 4: Imaging studies for aortic aneurysm
An abnormal chest radiograph with a prominent aortic shadow or mediastinal widening should prompt further evaluation for TAA. In addition, patients with known abdominal aortic aneurysm should have the rest of the aorta imaged as well to rule out associated TAA.

Imaging tests

Figure 2. Echocardiographic image of an aneurysmal aortic root (white arrow) that tapers to normal dimensions at the sinotubular junction (yellow arrow) and ascending aorta.
Figure 2. Echocardiographic image of an aneurysmal aortic root (white arrow) that tapers to normal dimensions at the sinotubular junction (yellow arrow) and ascending aorta.
TAA can be diagnosed with several imaging tests, each with advantages and disadvantages (Table 4).12 Most commonly used in its diagnosis and follow-up are transthoracic echocardiography (Figure 2 [video 1, video 2]), cardiac-gated computed tomographic angiography (CTA), and MRI (Figure 3 [video 3, video 4, video 5]). Transesophageal echocardiography is not routinely used in diagnosing TAA but is invaluable during surgery to assess aortic valve function and immediate results of aortic repair.

Figure 3. An aortic root aneurysm in a patient with Marfan syndrome using magnetic resonance angiography.
Figure 3. An aortic root aneurysm in a patient with Marfan syndrome using magnetic resonance angiography.
Which imaging test to use depends on the clinical context as well as the availability and expertise at each institution. For example, screening of first-degree relatives of a patient with thoracic aortic disease typically begins with transthoracic echocardiography and can be escalated to CTA or MRI if an abnormality is detected. Alternatively, patients with connective tissue disease with a particularly severe vascular phenotype such as Loeys-Dietz syndrome should undergo screening with dedicated aortic imaging such as CTA, since this disease can affect the entire aorta and its branch vessels.

Figure 4. Top, 3D reconstruction of an ascending aortic aneurysm in a patient with a bicuspid aortic valve. Bottom, 3D reconstruction of a young patient with an aortic root aneurysm.
Figure 4. Top, 3D reconstruction of an ascending aortic aneurysm in a patient with a bicuspid aortic valve. Bottom, 3D reconstruction of a young patient with an aortic root aneurysm. Note the tapering from the aneurysmal aortic root to the normal-sized ascending aorta. LMCA = left main coronary artery; RCA = right coronary artery.
The aortic diameter should be measured perpendicularly to the centerline of flow, which is now easier with dedicated aortic imaging technology and widely available, user-friendly, 3-dimensional reconstruction software (Figure 4 [video 6]).2

It is particularly important to obtain a gated CTA image in patients with aortic root aneurysm to avoid motion artifact and possible erroneous measurements. Gated CTA is done with electrocardiographic synchronization and allows for image processing to correct for cardiac motion.

 

 

HOW IS TAA CLASSIFIED?

TAA can be caused by a variety of inherited and sporadic conditions. These differences in pathogenesis lend themselves to classification of aneurysms into groups. Table 3 highlights the most common conditions associated with TAA.13

Bicuspid aortic valve aortopathy

From 1% to 2% of people have a bicuspid aortic valve, with a 3-to-1 male predominance.14,15 Aortic dilation occurs in 35% to 80% of people who have a bicuspid aortic valve, conferring a risk of dissection 8 times higher than in the general population.16–18

The pathogenic mechanisms that lead to this condition are widely debated, although a combination of genetic defects leading to intrinsic weakening of the aortic wall and hemodynamic effects likely contribute.19 Evidence of hemodynamic contributions to aortic dilation comes from findings that particular patterns of cusp fusion of the bicuspid aortic valve result in changes in transvalvular flow, placing more stress on specific regions of the ascending aorta.20,21 These hemodynamic alterations result in patterns of aortic dilation that depend on cusp fusion and the presence of valvular disease.

Multiple small studies found that replacing bicuspid aortic valves reduced the rate of aortic dilation, suggesting that hemodynamic factors may play a larger role than intrinsic wall properties in genetically susceptible individuals.22,23 However, larger studies are needed before any definitive conclusions can be made.

HOW IS ANEURYSM MANAGED ON AN OUTPATIENT BASIS?

Patients with a new diagnosis of TAA should be referred to a cardiologist with expertise in managing aortic disease or to a cardiac surgeon specializing in aortic surgery, depending on the initial size of the aneurysm.

Control blood pressure with beta-blockers

Medical management for patients with TAA has historically been limited to strict blood pressure control aimed at reducing aortic wall stress, mainly with beta-blockers.

Are angiotensin II receptor blockers (ARBs) beneficial? Studies in a mouse model of Marfan syndrome revealed that the ARB losartan attenuated aortic root growth.24 The results of early, small studies in humans were promising,25–27 but larger randomized trials have shown no advantage of losartan over beta-blockers in slowing aortic root growth.28 These negative results led many to question the effectiveness of losartan, although some point out that no studies have shown even beta-blockers to be beneficial in reducing the clinical end points of death or dissection.29 On the other hand, patients with certain FBN1 mutations respond more readily than others to losartan.30 Additional clinical trials of ARBs in Marfan syndrome are ongoing.

Current guidelines recommend stringent blood pressure control and smoking cessation for patients with a small aneurysm not requiring surgery and for those who are considered unsuitable for surgical or percutaneous intervention (level of evidence C, the lowest).2 For patients with TAA, it is considered reasonable to give beta-blockers. Angiotensin-converting enzyme inhibitors or ARBs may be used in combination with beta-blockers, titrated to the lowest tolerable blood pressure without adverse effects (level of evidence B).2

The recommended target blood pressure is less than 140/90 mm Hg, or 130/80 mm Hg in those with diabetes or chronic kidney disease (level of evidence B).2 However, we recommend more stringent blood pressure control: ie, less than 130/80 mm Hg for all patients with aortic aneurysm and a heart rate goal of 70 beats per minute or less, as tolerated.

Activity restriction

Activity restrictions for patients with TAA are largely based on theory, and certain activities may require more modification than others. For example, heavy lifting should be discouraged, as it may increase blood pressure significantly for short periods of time.2,31 The increased wall stress, in theory, could initiate dissection or rupture. However, moderate-intensity aerobic activity is rarely associated with significant elevations in blood pressure and should be encouraged. Stressful emotional states have been anecdotally associated with aortic dissection; thus, measures to reduce stress may offer some benefit.31

Our recommendations. While there are no published guidelines regarding activity restrictions in patients with TAA, we use a graded approach based on aortic diameter:

  • 4.0 to 4.4 cm—lift no more than 75 pounds
  • 4.5 to 5 cm—lift no more than 50 pounds
  • 5 cm—lift no more than 25 pounds.

We also recommend not lifting anything heavier than half of one’s body weight and to avoid breath-holding or performing the Valsalva maneuver while lifting. Although these recommendations are somewhat arbitrary, based on theory and a large clinical experience at our aortic center, they seem reasonable and practical.

Activity restrictions should be stringent and individualized in patients with Marfan, Loeys-Dietz, or Ehlers-Danlos syndrome due to increased risk of dissection or rupture even if the aorta is normal in size.

We sometimes recommend exercise stress testing to assess the heart rate and blood pressure response to exercise, and we are developing research protocols to help tailor activity recommendations.

 

 

WHEN SHOULD A PATIENT BE REFERRED?

To a cardiologist at the time of diagnosis

As soon as TAA is diagnosed, the patient should be referred to a cardiologist who has special interest in aortic disease. This will allow for appropriate and timely decisions about medical management, imaging, follow-up, and referral to surgery. Additional recommendations for screening of family members and referral to clinical geneticists can be discussed at this juncture. Activity restrictions should be reviewed at the initial evaluation.

To a surgeon relatively early

Size thresholds for surgical intervention are discussed below, but one should not wait until these thresholds are reached to send the patient for surgical consultation. It is beneficial to the state of mind of a potential surgical candidate to have early discussions pertaining to the types of operations available, their outcomes, and associated risks and benefits. If a patient’s aortic size remains stable over time, he or she may be followed by the cardiologist until significant size or growth has been documented, at which time the patient and surgeon can reconvene to discuss options for definitive treatment.

To a clinical geneticist

If 1 or more first-degree relatives of a patient with TAA or dissection are found to have aneurysmal disease, referral to a clinical geneticist is very important for genetic testing of multiple genes that have been implicated in thoracic aortic aneurysm and dissection.

WHEN SHOULD TAA BE REPAIRED?

Surgery to prevent rupture or dissection remains the definitive treatment of TAA when size thresholds are reached, and symptomatic aneurysm should be operated on regardless of the size. However, rarely are thoracic aneurysms symptomatic unless they rupture or dissect. The size criteria are based on underlying genetic etiology if known and on the behavior and natural course of TAA.

Size and other factors

Treatment should be tailored to the patient’s clinical scenario, family history, and estimated risk of rupture or dissection, balanced against the individual center’s outcomes of elective aortic replacement.32 For example, young and otherwise healthy patients with TAA and a family history of aortic dissection (who may be more likely to have connective tissue disorders such as Marfan syndrome, Loeys-Dietz syndrome, or vascular Ehler-Danlos syndrome) may elect to undergo repair when the aneurysm reaches or nearly reaches the diameter of that of the family member’s aorta when dissection occurred.2 On the other hand, TAA of degenerative etiology (eg, related to smoking or hypertension) measuring less than 5.5 cm in an older patient with comorbidities poses a lower risk of a catastrophic event such as dissection or rupture than the risk of surgery.11

Thresholds for surgery. Once the diameter of the ascending aorta reaches 6 cm, the likelihood of an acute dissection is 31%.11 A similar threshold is reached for the descending aorta at a size of 7 cm.11 Therefore, to avoid high-risk emergency surgery on an acutely dissected aorta, surgery on an ascending aortic aneurysm of degenerative etiology is usually suggested when the aneurysm reaches 5.5 cm or a documented growth rate greater than 0.5 cm/year.2,33

Additionally, in patients already undergoing surgery for valvular or coronary disease, prophylactic aortic replacement is recommended if the ascending aorta is larger than 4.5 cm. The threshold for intervention is lower in patients with connective tissue disease (> 5.0 cm for Marfan syndrome, 4.4–4.6 cm for Loeys-Dietz syndrome).2,33

Observational studies suggest that the risk of aortic complications in patients with bicuspid aortic valve aortopathy is low overall, though significantly greater than in the general population.18,34,35 These findings led to changes in the 2014 American College of Cardiology/American Heart Association guidelines on valvular heart disease,36 suggesting a surgical threshold of 5.5 cm in the absence of significant valve disease or family history of dissection of an aorta of smaller diameter.

A 2015 study of dissection risk in patients with bicuspid aortic valve aortopathy by our group found a dramatic increase in risk of aortic dissection for ascending aortic diameters greater than 5.3 cm, and a gradual increase in risk for aortic root diameters greater than 5.0 cm.37 In addition, a near-constant 3% to 4% risk of dissection was present for aortic diameters ranging from 4.7 cm to 5.0 cm, revealing that watchful waiting carries its own inherent risks.37 In our surgical experience with this population, the hospital mortality rate and risk of stroke from aortic surgery were 0.25% and 0.75%, respectively.37 Thus, the decision to operate for aortic aneurysm in the setting of a bicuspid aortic valve should take into account patient-specific factors and institutional outcomes.

A statement of clarification in the American College of Cardiology/American Heart Association guidelines was published in 2015, recommending surgery for patients with an aortic diameter of 5.0 cm or greater if the patient is at low risk and the surgery is performed by an experienced surgical team at a center with established surgical expertise in this condition.38 However, current recommendations are for surgery at 5.5 cm if the above conditions are not met.

Ratio of aortic cross-sectional area to height

Although size alone has long been used to guide surgical intervention, a recent review from the International Registry of Aortic Dissection revealed that 59% of patients suffered aortic dissection at diameters less than 5.5 cm, and that patients with certain connective tissue diseases such as Loeys-Dietz syndrome or familial thoracic aneurysm and dissection had a documented propensity for dissection at smaller diameters.39–41

Size indices such as the aortic cross-sectional area indexed to height have been implemented in guidelines for certain patient populations (eg, 10 cm2/m in Marfan syndrome) and provide better risk stratification than size cutoffs alone.2,42

The ratio of aortic cross-sectional area to the patient’s height has also been applied to patients with bicuspid aortic valve-associated aortopathy and to those with a dilated aorta and a tricuspid aortic valve.43,44 Notably, a ratio greater than 10 cm2/m has been associated with aortic dissection in these groups, and this cutoff provides better stratification for prediction of death than traditional size metrics.27,28

 

 

HOW SHOULD PATIENTS BE SCREENED? WHAT FOLLOW-UP IS NECESSARY?

Initial screening and follow-up

Follow-up of TAA depends on the initial aortic size or rate of growth, or both. For patients presenting for the first time with TAA, it is reasonable to obtain definitive aortic imaging with CT or magnetic resonance angiography (MRA), then to repeat imaging at 6 months to document stability. If the aortic dimensions remain stable, then annual follow-up with CT or MRA is reasonable.2

Figure 5. Initial screening and follow-up of thoracic aortic aneurysm.
Figure 5. Initial screening and follow-up of thoracic aortic aneurysm.
MRA may be preferable to CT over the long term to limit radiation exposure.2 Echocardiography should be used if the aortic root or ascending aorta is well visualized, but in most patients the view of the mid to distal ascending aorta is limited. Echocardiography also offers evaluation of left ventricular size and function and allows for follow-up of aortic valve disease.

Our flow chart of initial screening and follow-up is shown in Figure 5.

Screening of family members

In our center, we routinely recommend screening of all first-degree relatives of patients with TAA. Aortic imaging with echocardiography plus CT or MRI should be considered to detect asymptomatic disease.2 In patients with a strong family history (ie, multiple relatives affected with aortic aneurysm, dissection, or sudden cardiac death), genetic screening and testing for known mutations are recommended for the patient as well as for the family members.

If a mutation is identified in a family, then first-degree relatives should undergo genetic screening for the mutation and aortic imaging.2 Imaging in second-degree relatives may also be considered if one or more first-degree relatives are found to have aortic dilation.2

We recommend similar screening of first-degree family members of patients with bicuspid aortic valve aortopathy. In patients with young children, we recommend obtaining an echocardiogram of the child to look for a bicuspid aortic valve or aortic dilation. If an abnormality is detected or suspected, dedicated imaging with MRA to assess aortic dimensions is warranted.

BACK TO OUR PATIENT WITH A BICUSPID AORTIC VALVE

Our patient with a bicuspid aortic valve had a 4.6-cm root, an ascending aortic aneurysm, and several affected family members.

We would obtain dedicated aortic imaging at this patient’s initial visit with either gated CT with contrast or MRA, and we would obtain a cardioaortic surgery consult. We would repeat these studies at a follow-up visit 6 months later to detect any aortic growth compared with initial studies, and follow up annually thereafter. Echocardiography can also be done at the initial visit to determine if valvular disease is present that may influence clinical decisions.

Surgery would likely be recommended once the root reached a maximum area-to-height ratio greater than 10 cm2/m, or if the valve became severely dysfunctional during follow-up.

BACK TO OUR PATIENT WITH MARFAN SYNDROME

The young woman with Marfan syndrome has a 4.6-cm aortic root aneurysm and 2+ aortic insufficiency. Her question pertains to the threshold at which an operation would be considered. This question is complicated and is influenced by several concurrent clinical features in her presentation.

Starting with size criteria, patients with Marfan syndrome should be considered for elective aortic root repair at a diameter greater than 5 cm. However, an aortic cross-sectional area-to-height ratio greater than 10 cm2/m may provide a more robust metric for clinical decision-making than aortic diameter alone. Additional factors such as degree of aortic insufficiency and deleterious left ventricular remodeling may urge one to consider aortic root repair at a diameter of 4.5 cm.

These factors, including rate of growth and the surgeon’s assessment about his or her ability to preserve the aortic valve during repair, should be considered collectively in this scenario.

References
  1. Elefteriades JA, Farkas EA. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol 2010; 55(9):841–857. doi:10.1016/j.jacc.2009.08.084
  2. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. Anesth Analg 2010; 111(2):279–315. doi:10.1213/ANE.0b013e3181dd869b
  3. Clouse WD, Hallett JW Jr, Schaff HV, Gayari MM, Ilstrup DM, Melton LJ 3rd. Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA 1998; 280(22):1926–1929. pmid:9851478
  4. Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation 2006; 114(24):2611–2618. doi:10.1161/CIRCULATIONAHA.106.630400
  5. Clouse WD, Hallett JW Jr, Schaff HV, et al. Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture. Mayo Clin Proc 2004; 79(2):176–180. pmid:14959911
  6. US Centers for Disease Control and Prevention (CDC). National Center for Injury Prevention and Control. WISQARS leading causes of death reports, 1999 – 2007. https://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html. Accessed May 21, 2018.
  7. Hansen MS, Nogareda GJ, Hutchison SJ. Frequency of and inappropriate treatment of misdiagnosis of acute aortic dissection. Am J Cardiol 2007; 99(6):852–856. doi:10.1016/j.amjcard.2006.10.055
  8. Goldfinger JZ, Halperin JL, Marin ML, Stewart AS, Eagle KA, Fuster V. Thoracic aortic aneurysm and dissection. J Am Coll Cardiol 2014; 64(16):1725–1739. doi:10.1016/j.jacc.2014.08.025
  9. Kumar V, Abbas A, Aster J. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA: Elsevier/Saunders; 2015.
  10. Wolak A, Gransar H, Thomson LE, et al. Aortic size assessment by noncontrast cardiac computed tomography: normal limits by age, gender, and body surface area. JACC Cardiovasc Imaging 2008; 1(2):200–209. doi:10.1016/j.jcmg.2007.11.005
  11. Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg 2002; 74(5):S1877–S1880; discussion S1892–S1898. pmid:12440685
  12. Smith AD, Schoenhagen P. CT imaging for acute aortic syndrome. Cleve Clin J Med 2008; 75(1):7–17. pmid:18236724
  13. Cury M, Zeidan F, Lobato AC. Aortic disease in the young: genetic aneurysm syndromes, connective tissue disorders, and familial aortic aneurysms and dissections. Int J Vasc Med 2013(2013); 2013:267215. doi:10.1155/2013/267215
  14. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39(12):1890–1900. doi:10.1016/S0735-1097(02)01886-7
  15. Fedak PW, Verma S, David TE, Leask RL, Weisel RD, Butany J. Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation 2002; 106(8):900–904. pmid:12186790
  16. Della Corte A, Bancone C, Quarto C, et al. Predictors of ascending aortic dilatation with bicuspid aortic valve: a wide spectrum of disease expression. Eur J Cardiothorac Surg 2007; 31(3):397–405. doi:10.1016/j.ejcts.2006.12.006
  17. Jackson V, Petrini J, Caidahl K, et al. Bicuspid aortic valve leaflet morphology in relation to aortic root morphology: a study of 300 patients undergoing open-heart surgery. Eur J Cardiothorac Surg 2011; 40(3):e118–e124. doi:10.1016/j.ejcts.2011.04.014
  18. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011; 306(10):1104–1112. doi:10.1001/jama.2011.1286
  19. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med 2014; 370(20):1920–1929. doi:10.1056/NEJMra1207059
  20. Barker AJ, Markl M, Bürk J, et al. Bicuspid aortic valve is associated with altered wall shear stress in the ascending aorta. Circ Cardiovasc Imaging 2012; 5(4):457–466. doi:10.1161/CIRCIMAGING.112.973370
  21. Hope MD, Hope TA, Meadows AK, et al. Bicuspid aortic valve: four-dimensional MR evaluation of ascending aortic systolic flow patterns. Radiology 2010; 255(1):53–61. doi:10.1148/radiol.09091437
  22. Abdulkareem N, Soppa G, Jones S, Valencia O, Smelt J, Jahangiri M. Dilatation of the remaining aorta after aortic valve or aortic root replacement in patients with bicuspid aortic valve: a 5-year follow-up. Ann Thorac Surg 2013; 96(1):43–49. doi:10.1016/j.athoracsur.2013.03.086
  23. Regeer MV, Versteegh MI, Klautz RJ, et al. Effect of aortic valve replacement on aortic root dilatation rate in patients with bicuspid and tricuspid aortic valves. Ann Thorac Surg 2016; 102(6):1981–1987. doi:10.1016/j.athoracsur.2016.05.038
  24. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312(5770):117–121. doi:10.1126/science.1124287
  25. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med 2008; 358(26):2787–2795. doi:10.1056/NEJMoa0706585
  26. Chiu HH, Wu MH, Wang JK, et al. Losartan added to ß-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc 2013; 88(3):271–276. doi:10.1016/j.mayocp.2012.11.005
  27. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013; 34(45):3491–3500. doi:10.1093/eurheartj/eht334
  28. Lacro RV, Dietz HC, Sleeper LA, et al; Pediatric Heart Network Investigators. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med 2014; 371(22):2061–2071. doi:10.1056/NEJMoa1404731
  29. Ziganshin BA, Mukherjee SK, Elefteriades JA, et al. Atenolol versus losartan in Marfan’s syndrome (letters). N Engl J Med 2015; 372(10):977–981. doi:10.1056/NEJMc1500128
  30. Franken R, den Hartog AW, Radonic T, et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ Cardiovasc Genet 2015; 8(2):383–388. doi:10.1161/CIRCGENETICS.114.000950
  31. Elefteriades JA. Thoracic aortic aneurysm: reading the enemy’s playbook. Curr Probl Cardiol 2008; 33(5):203–277. doi:10.1016/j.cpcardiol.2008.01.004
  32. Idrees JJ, Roselli EE, Lowry AM, et al. Outcomes after elective proximal aortic replacement: a matched comparison of isolated versus multicomponent operations. Ann Thorac Surg 2016; 101(6):2185–2192. doi:10.1016/j.athoracsur.2015.12.026
  33. Hiratzka LF, Creager MA, Isselbacher EM, et al. Surgery for aortic dilatation in patients with bicuspid aortic valves: a statement of clarification from the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 2016; 151(4):959–966. doi:10.1016/j.jtcvs.2015.12.001
  34. Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid aortic valves. JAMA 2008; 300(11):1317–1325. doi:10.1001/jama.300.11.1317
  35. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002; 73(1):17–28. pmid:11834007
  36. Nishimura RA, Otto CM, Bono RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American heart Association Task Force on Practice Guidelines. Circulation 2014; 129(23):2440–2492. doi:10.1161/CIR.0000000000000029
  37. Wojnarski CM, Svensson LG, Roselli EE, et al. Aortic dissection in patients with bicuspid aortic valve–associated aneurysms. Ann Thorac Surg 2015; 100(5):1666–1674. doi:10.1016/j.athoracsur.2015.04.126
  38. Hiratzka LF, Creager MA, Isselbacher EM, et al. Surgery for aortic dilatation in patients with bicuspid aortic valves: a statement of clarification from the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016; 133(7):680–686. doi:10.1161/CIR.0000000000000331
  39. Pape LA, Tsai TT, Isselbacher EM, et al; International Registry of Acute Aortic Dissection (IRAD) Investigators. Aortic diameter > or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2007; 116(10):1120–1127. doi:10.1161/CIRCULATIONAHA.107.702720
  40. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006; 355(8):788–798. doi:10.1056/NEJMoa055695
  41. Guo DC, Pannu H, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 2007; 39(12):1488–1493. doi:10.1038/ng.2007.6
  42. Svensson LG, Khitin L. Aortic cross-sectional area/height ratio timing of aortic surgery in asymptomatic patients with Marfan syndrome. J Thorac Cardiovasc Surg 2002; 123(2):360–361. pmid:11828302
  43. Svensson LG, Kim KH, Lytle BW, Cosgrove DM. Relationship of aortic cross-sectional area to height ratio and the risk of aortic dissection in patients with bicuspid aortic valves. J Thorac Cardiovasc Surg 2003; 126(3):892–893. pmid:14502185
  44. Masri A, Kalahasti V, Svensson LG, et al. Aortic cross-sectional area/height ratio and outcomes in patients with a trileaflet aortic valve and a dilated aorta. Circulation 2016; 134(22):1724–1737. doi:10.1161/CIRCULATIONAHA.116.022995
Article PDF
Author and Disclosure Information

Frank Cikach, MD
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Milind Y. Desai, MD, FACC, FAHA, FESC
Haslam Family Endowed Chair in Cardiovascular Medicine, Department of Cardiovascular Medicine, Medical Director, Aorta Center, Heart and Vascular Institute, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Eric E. Roselli, MD, FACS
Chief, Adult Cardiac Surgery, Surgical Director, Aorta Center, Director, Heart and Vascular Condition Centers, Heart and Vascular Institute, Cleveland Clinic; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Vidyasagar Kalahasti, MD
Director, Marfan and Other Connective Tissue Disorders Clinic, Aorta Center, Heart and Vascular Institute, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Address: Vidyasagar Kalahasti, MD, Heart and Vascular Institute, J1-5, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; kalahav@ccf.org

Dr. Roselli has disclosed consulting for Bolton Medical, Medtronic, Sorin Group, and W.L. Gore & Associates and teaching and speaking for Cook Medical, Edwards Lifesciences, Sorin Group, St. Jude Medical, and Terumo.  

Issue
Cleveland Clinic Journal of Medicine - 85(6)
Publications
Topics
Page Number
481-492
Legacy Keywords
thoracic aortic aneurysm, aorta, bicuspid aortic valve, Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, dilation, mutations, beta-blockers, dissection, rupture, Frank Cikach, Milind Desai, Eric Roselli, Vidyasagar Kalahasti
Sections
Author and Disclosure Information

Frank Cikach, MD
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Milind Y. Desai, MD, FACC, FAHA, FESC
Haslam Family Endowed Chair in Cardiovascular Medicine, Department of Cardiovascular Medicine, Medical Director, Aorta Center, Heart and Vascular Institute, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Eric E. Roselli, MD, FACS
Chief, Adult Cardiac Surgery, Surgical Director, Aorta Center, Director, Heart and Vascular Condition Centers, Heart and Vascular Institute, Cleveland Clinic; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Vidyasagar Kalahasti, MD
Director, Marfan and Other Connective Tissue Disorders Clinic, Aorta Center, Heart and Vascular Institute, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Address: Vidyasagar Kalahasti, MD, Heart and Vascular Institute, J1-5, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; kalahav@ccf.org

Dr. Roselli has disclosed consulting for Bolton Medical, Medtronic, Sorin Group, and W.L. Gore & Associates and teaching and speaking for Cook Medical, Edwards Lifesciences, Sorin Group, St. Jude Medical, and Terumo.  

Author and Disclosure Information

Frank Cikach, MD
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Milind Y. Desai, MD, FACC, FAHA, FESC
Haslam Family Endowed Chair in Cardiovascular Medicine, Department of Cardiovascular Medicine, Medical Director, Aorta Center, Heart and Vascular Institute, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Eric E. Roselli, MD, FACS
Chief, Adult Cardiac Surgery, Surgical Director, Aorta Center, Director, Heart and Vascular Condition Centers, Heart and Vascular Institute, Cleveland Clinic; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Vidyasagar Kalahasti, MD
Director, Marfan and Other Connective Tissue Disorders Clinic, Aorta Center, Heart and Vascular Institute, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Address: Vidyasagar Kalahasti, MD, Heart and Vascular Institute, J1-5, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; kalahav@ccf.org

Dr. Roselli has disclosed consulting for Bolton Medical, Medtronic, Sorin Group, and W.L. Gore & Associates and teaching and speaking for Cook Medical, Edwards Lifesciences, Sorin Group, St. Jude Medical, and Terumo.  

Article PDF
Article PDF
Related Articles

Thoracic aortic aneurysm (TAA) needs to be detected, monitored, and managed in a timely manner to prevent a serious consequence such as acute dissection or rupture. But only about 5% of patients experience symptoms before an acute event occurs, and for the other 95% the first “symptom” is often death.1 Most cases are detected either incidentally with echocardiography, computed tomography (CT), or magnetic resonance imaging (MRI) during workup for another condition. Patients may also be diagnosed during workup of a murmur or after a family member is found to have an aneurysm. Therefore, its true incidence is difficult to determine.2

With these facts in mind, how would you manage the following 2 cases?

Case 1: Bicuspid aortic valve, ascending aortic aneurysm

A 45-year-old man with stage 1 hypertension presents for evaluation of a bicuspid aortic valve and ascending aortic aneurysm. He has several first-degree relatives with similar conditions, and his brother recently underwent elective aortic repair. At the urging of his primary care physician, he underwent screening echocardiography, which demonstrated a “dilated root and ascending aorta” 4.6 cm in diameter. He presents today to discuss management options and how the aneurysm could affect his everyday life.

Case 2: Marfan syndrome in a young woman

A 24-year-old woman with Marfan syndrome diagnosed in adolescence presents for annual follow-up. She has many family members with the same condition, and several have undergone prophylactic aortic root repair. Her aortic root has been monitored annually for progression of dilation, and today it is 4.6 cm in diameter, a 3-mm increase from the last measurement. She has grade 2+ aortic insufficiency (on a scale of 1+ to 4+) based on echocardiography, but she has no symptoms. She is curious about what size her aortic root will need to reach for surgery to be considered.

LIKELY UNDERDETECTED

TAA is being detected more often than in the past thanks to better detection methods and heightened awareness among physicians and patients. While an incidence rate of 10.4 per 100,000 patient-years is often cited,3 this figure likely underestimates the true incidence of this clinically silent condition. The most robust data come from studies based on in-hospital diagnostic codes coupled with data from autopsies for out-of-hospital deaths.

Olsson et al,4 in a 2016 study in Sweden, found the incidence of TAA and aortic dissection to be 16.3 per 100,000 per year for men and 9.1 per 100,000 per year for women.

Clouse et al5 reported the incidence of thoracic aortic dissection as 3.5 per 100,000 patient-years, and the same figure for thoracic aortic rupture. 

Aneurysmal disease accounts for 52,000 deaths per year in the United States, making it the 19th most common cause of death.6 These figures are likely lower than the true mortality rate for this condition, given that aortic dissection is often mistaken for acute myocardial infarction or other acute event if an autopsy is not done to confirm the cause of death.7

RISK FACTORS FOR THORACIC AORTIC ANEURYSM

Risk factors for TAA include genetic conditions that lead to aortic medial weakness or destruction such as Loeys-Dietz syndrome and Marfan syndrome.2 In addition, family history is important even in the absence of known genetic mutations. Other risk factors include conditions that increase aortic wall stress, such as hypertension, cocaine abuse, extreme weightlifting, trauma, and aortic coarctation.2

DIAMETER INCREASES WITH AGE, BODY SURFACE AREA

Figure 1.
Figure 1.
The thoracic aorta consists of the root and the ascending, arch, and descending segments (Figure 1); the abdominal aorta consists of the suprarenal and infrarenal segments.8,9 These divisions are useful, as aneurysmal disease can be confined to specific locations along the length of the vessel, and the location can affect the clinical presentation and management decisions and lend insight into the pathogenesis.

Normal dimensions for the aortic segments differ depending on age, sex, and body surface area.8,44,45 The size of the aortic root may also vary depending on how it is measured, due to the root’s trefoil shape. Measured sinus to sinus, the root is larger than when measured sinus to commissure on CT angiography or cardiac MRI. It is also larger when measured leading edge to leading edge than inner edge to inner edge on echocardiography.10

TAA is defined as an aortic diameter at least 50% greater than the upper limit of normal.8 

Aortic diameters: Upper limits of normal
The aorta increases in diameter by 0.7 to 1.9 mm per year if not dilated, and larger-diameter aortas grow faster.11 In addition, men have a larger aortic diameter than women.10 Size-based criteria and indices are useful for defining and monitoring aneurysmal progression, since larger patients tend to have a larger aorta.10  Table 1 lists upper limits of normal values for the ascending and descending aorta by age, sex, and body surface area obtained by Wolak et al in a study using noncontrast CT.10

Geometric changes in the curvature of the ascending aorta, aortic arch, and descending thoracic aorta can occur as the result of hypertension, atherosclerosis, or connective tissue disease. 

 

 

HOW IS TAA DIAGNOSED?

Table 2: Common causes of thoracic aortic aneurysm
TAA is asymptomatic in most patients and is usually detected on imaging. However, it should be actively looked for in patients who have a family history of Marfan, Loeys-Dietz, or Ehlers-Danlos syndrome or a family history of aortic aneurysm or dissection (not necessarily in a first-degree relative, but more significant in a first-degree relative or in multiple family members across generations), and in patients with a bicuspid aortic valve or autoimmune disease such as Takayasu or giant cell arteritis (Table 2). Table 3 lists the common genetic disorders with their associated mutations and clinical features.

Table 3: Inherited connective tissue diseases and thoracic aortic aneurysm
Some patients present with chest pain that may be related to local compression due to the aorta’s large size. Hoarseness, dysphagia, or chronic cough may be a presenting symptom, particularly in patients with descending aortic aneurysm or congenital aortic anomaly.

Table 4: Imaging studies for aortic aneurysm
An abnormal chest radiograph with a prominent aortic shadow or mediastinal widening should prompt further evaluation for TAA. In addition, patients with known abdominal aortic aneurysm should have the rest of the aorta imaged as well to rule out associated TAA.

Imaging tests

Figure 2. Echocardiographic image of an aneurysmal aortic root (white arrow) that tapers to normal dimensions at the sinotubular junction (yellow arrow) and ascending aorta.
Figure 2. Echocardiographic image of an aneurysmal aortic root (white arrow) that tapers to normal dimensions at the sinotubular junction (yellow arrow) and ascending aorta.
TAA can be diagnosed with several imaging tests, each with advantages and disadvantages (Table 4).12 Most commonly used in its diagnosis and follow-up are transthoracic echocardiography (Figure 2 [video 1, video 2]), cardiac-gated computed tomographic angiography (CTA), and MRI (Figure 3 [video 3, video 4, video 5]). Transesophageal echocardiography is not routinely used in diagnosing TAA but is invaluable during surgery to assess aortic valve function and immediate results of aortic repair.

Figure 3. An aortic root aneurysm in a patient with Marfan syndrome using magnetic resonance angiography.
Figure 3. An aortic root aneurysm in a patient with Marfan syndrome using magnetic resonance angiography.
Which imaging test to use depends on the clinical context as well as the availability and expertise at each institution. For example, screening of first-degree relatives of a patient with thoracic aortic disease typically begins with transthoracic echocardiography and can be escalated to CTA or MRI if an abnormality is detected. Alternatively, patients with connective tissue disease with a particularly severe vascular phenotype such as Loeys-Dietz syndrome should undergo screening with dedicated aortic imaging such as CTA, since this disease can affect the entire aorta and its branch vessels.

Figure 4. Top, 3D reconstruction of an ascending aortic aneurysm in a patient with a bicuspid aortic valve. Bottom, 3D reconstruction of a young patient with an aortic root aneurysm.
Figure 4. Top, 3D reconstruction of an ascending aortic aneurysm in a patient with a bicuspid aortic valve. Bottom, 3D reconstruction of a young patient with an aortic root aneurysm. Note the tapering from the aneurysmal aortic root to the normal-sized ascending aorta. LMCA = left main coronary artery; RCA = right coronary artery.
The aortic diameter should be measured perpendicularly to the centerline of flow, which is now easier with dedicated aortic imaging technology and widely available, user-friendly, 3-dimensional reconstruction software (Figure 4 [video 6]).2

It is particularly important to obtain a gated CTA image in patients with aortic root aneurysm to avoid motion artifact and possible erroneous measurements. Gated CTA is done with electrocardiographic synchronization and allows for image processing to correct for cardiac motion.

 

 

HOW IS TAA CLASSIFIED?

TAA can be caused by a variety of inherited and sporadic conditions. These differences in pathogenesis lend themselves to classification of aneurysms into groups. Table 3 highlights the most common conditions associated with TAA.13

Bicuspid aortic valve aortopathy

From 1% to 2% of people have a bicuspid aortic valve, with a 3-to-1 male predominance.14,15 Aortic dilation occurs in 35% to 80% of people who have a bicuspid aortic valve, conferring a risk of dissection 8 times higher than in the general population.16–18

The pathogenic mechanisms that lead to this condition are widely debated, although a combination of genetic defects leading to intrinsic weakening of the aortic wall and hemodynamic effects likely contribute.19 Evidence of hemodynamic contributions to aortic dilation comes from findings that particular patterns of cusp fusion of the bicuspid aortic valve result in changes in transvalvular flow, placing more stress on specific regions of the ascending aorta.20,21 These hemodynamic alterations result in patterns of aortic dilation that depend on cusp fusion and the presence of valvular disease.

Multiple small studies found that replacing bicuspid aortic valves reduced the rate of aortic dilation, suggesting that hemodynamic factors may play a larger role than intrinsic wall properties in genetically susceptible individuals.22,23 However, larger studies are needed before any definitive conclusions can be made.

HOW IS ANEURYSM MANAGED ON AN OUTPATIENT BASIS?

Patients with a new diagnosis of TAA should be referred to a cardiologist with expertise in managing aortic disease or to a cardiac surgeon specializing in aortic surgery, depending on the initial size of the aneurysm.

Control blood pressure with beta-blockers

Medical management for patients with TAA has historically been limited to strict blood pressure control aimed at reducing aortic wall stress, mainly with beta-blockers.

Are angiotensin II receptor blockers (ARBs) beneficial? Studies in a mouse model of Marfan syndrome revealed that the ARB losartan attenuated aortic root growth.24 The results of early, small studies in humans were promising,25–27 but larger randomized trials have shown no advantage of losartan over beta-blockers in slowing aortic root growth.28 These negative results led many to question the effectiveness of losartan, although some point out that no studies have shown even beta-blockers to be beneficial in reducing the clinical end points of death or dissection.29 On the other hand, patients with certain FBN1 mutations respond more readily than others to losartan.30 Additional clinical trials of ARBs in Marfan syndrome are ongoing.

Current guidelines recommend stringent blood pressure control and smoking cessation for patients with a small aneurysm not requiring surgery and for those who are considered unsuitable for surgical or percutaneous intervention (level of evidence C, the lowest).2 For patients with TAA, it is considered reasonable to give beta-blockers. Angiotensin-converting enzyme inhibitors or ARBs may be used in combination with beta-blockers, titrated to the lowest tolerable blood pressure without adverse effects (level of evidence B).2

The recommended target blood pressure is less than 140/90 mm Hg, or 130/80 mm Hg in those with diabetes or chronic kidney disease (level of evidence B).2 However, we recommend more stringent blood pressure control: ie, less than 130/80 mm Hg for all patients with aortic aneurysm and a heart rate goal of 70 beats per minute or less, as tolerated.

Activity restriction

Activity restrictions for patients with TAA are largely based on theory, and certain activities may require more modification than others. For example, heavy lifting should be discouraged, as it may increase blood pressure significantly for short periods of time.2,31 The increased wall stress, in theory, could initiate dissection or rupture. However, moderate-intensity aerobic activity is rarely associated with significant elevations in blood pressure and should be encouraged. Stressful emotional states have been anecdotally associated with aortic dissection; thus, measures to reduce stress may offer some benefit.31

Our recommendations. While there are no published guidelines regarding activity restrictions in patients with TAA, we use a graded approach based on aortic diameter:

  • 4.0 to 4.4 cm—lift no more than 75 pounds
  • 4.5 to 5 cm—lift no more than 50 pounds
  • 5 cm—lift no more than 25 pounds.

We also recommend not lifting anything heavier than half of one’s body weight and to avoid breath-holding or performing the Valsalva maneuver while lifting. Although these recommendations are somewhat arbitrary, based on theory and a large clinical experience at our aortic center, they seem reasonable and practical.

Activity restrictions should be stringent and individualized in patients with Marfan, Loeys-Dietz, or Ehlers-Danlos syndrome due to increased risk of dissection or rupture even if the aorta is normal in size.

We sometimes recommend exercise stress testing to assess the heart rate and blood pressure response to exercise, and we are developing research protocols to help tailor activity recommendations.

 

 

WHEN SHOULD A PATIENT BE REFERRED?

To a cardiologist at the time of diagnosis

As soon as TAA is diagnosed, the patient should be referred to a cardiologist who has special interest in aortic disease. This will allow for appropriate and timely decisions about medical management, imaging, follow-up, and referral to surgery. Additional recommendations for screening of family members and referral to clinical geneticists can be discussed at this juncture. Activity restrictions should be reviewed at the initial evaluation.

To a surgeon relatively early

Size thresholds for surgical intervention are discussed below, but one should not wait until these thresholds are reached to send the patient for surgical consultation. It is beneficial to the state of mind of a potential surgical candidate to have early discussions pertaining to the types of operations available, their outcomes, and associated risks and benefits. If a patient’s aortic size remains stable over time, he or she may be followed by the cardiologist until significant size or growth has been documented, at which time the patient and surgeon can reconvene to discuss options for definitive treatment.

To a clinical geneticist

If 1 or more first-degree relatives of a patient with TAA or dissection are found to have aneurysmal disease, referral to a clinical geneticist is very important for genetic testing of multiple genes that have been implicated in thoracic aortic aneurysm and dissection.

WHEN SHOULD TAA BE REPAIRED?

Surgery to prevent rupture or dissection remains the definitive treatment of TAA when size thresholds are reached, and symptomatic aneurysm should be operated on regardless of the size. However, rarely are thoracic aneurysms symptomatic unless they rupture or dissect. The size criteria are based on underlying genetic etiology if known and on the behavior and natural course of TAA.

Size and other factors

Treatment should be tailored to the patient’s clinical scenario, family history, and estimated risk of rupture or dissection, balanced against the individual center’s outcomes of elective aortic replacement.32 For example, young and otherwise healthy patients with TAA and a family history of aortic dissection (who may be more likely to have connective tissue disorders such as Marfan syndrome, Loeys-Dietz syndrome, or vascular Ehler-Danlos syndrome) may elect to undergo repair when the aneurysm reaches or nearly reaches the diameter of that of the family member’s aorta when dissection occurred.2 On the other hand, TAA of degenerative etiology (eg, related to smoking or hypertension) measuring less than 5.5 cm in an older patient with comorbidities poses a lower risk of a catastrophic event such as dissection or rupture than the risk of surgery.11

Thresholds for surgery. Once the diameter of the ascending aorta reaches 6 cm, the likelihood of an acute dissection is 31%.11 A similar threshold is reached for the descending aorta at a size of 7 cm.11 Therefore, to avoid high-risk emergency surgery on an acutely dissected aorta, surgery on an ascending aortic aneurysm of degenerative etiology is usually suggested when the aneurysm reaches 5.5 cm or a documented growth rate greater than 0.5 cm/year.2,33

Additionally, in patients already undergoing surgery for valvular or coronary disease, prophylactic aortic replacement is recommended if the ascending aorta is larger than 4.5 cm. The threshold for intervention is lower in patients with connective tissue disease (> 5.0 cm for Marfan syndrome, 4.4–4.6 cm for Loeys-Dietz syndrome).2,33

Observational studies suggest that the risk of aortic complications in patients with bicuspid aortic valve aortopathy is low overall, though significantly greater than in the general population.18,34,35 These findings led to changes in the 2014 American College of Cardiology/American Heart Association guidelines on valvular heart disease,36 suggesting a surgical threshold of 5.5 cm in the absence of significant valve disease or family history of dissection of an aorta of smaller diameter.

A 2015 study of dissection risk in patients with bicuspid aortic valve aortopathy by our group found a dramatic increase in risk of aortic dissection for ascending aortic diameters greater than 5.3 cm, and a gradual increase in risk for aortic root diameters greater than 5.0 cm.37 In addition, a near-constant 3% to 4% risk of dissection was present for aortic diameters ranging from 4.7 cm to 5.0 cm, revealing that watchful waiting carries its own inherent risks.37 In our surgical experience with this population, the hospital mortality rate and risk of stroke from aortic surgery were 0.25% and 0.75%, respectively.37 Thus, the decision to operate for aortic aneurysm in the setting of a bicuspid aortic valve should take into account patient-specific factors and institutional outcomes.

A statement of clarification in the American College of Cardiology/American Heart Association guidelines was published in 2015, recommending surgery for patients with an aortic diameter of 5.0 cm or greater if the patient is at low risk and the surgery is performed by an experienced surgical team at a center with established surgical expertise in this condition.38 However, current recommendations are for surgery at 5.5 cm if the above conditions are not met.

Ratio of aortic cross-sectional area to height

Although size alone has long been used to guide surgical intervention, a recent review from the International Registry of Aortic Dissection revealed that 59% of patients suffered aortic dissection at diameters less than 5.5 cm, and that patients with certain connective tissue diseases such as Loeys-Dietz syndrome or familial thoracic aneurysm and dissection had a documented propensity for dissection at smaller diameters.39–41

Size indices such as the aortic cross-sectional area indexed to height have been implemented in guidelines for certain patient populations (eg, 10 cm2/m in Marfan syndrome) and provide better risk stratification than size cutoffs alone.2,42

The ratio of aortic cross-sectional area to the patient’s height has also been applied to patients with bicuspid aortic valve-associated aortopathy and to those with a dilated aorta and a tricuspid aortic valve.43,44 Notably, a ratio greater than 10 cm2/m has been associated with aortic dissection in these groups, and this cutoff provides better stratification for prediction of death than traditional size metrics.27,28

 

 

HOW SHOULD PATIENTS BE SCREENED? WHAT FOLLOW-UP IS NECESSARY?

Initial screening and follow-up

Follow-up of TAA depends on the initial aortic size or rate of growth, or both. For patients presenting for the first time with TAA, it is reasonable to obtain definitive aortic imaging with CT or magnetic resonance angiography (MRA), then to repeat imaging at 6 months to document stability. If the aortic dimensions remain stable, then annual follow-up with CT or MRA is reasonable.2

Figure 5. Initial screening and follow-up of thoracic aortic aneurysm.
Figure 5. Initial screening and follow-up of thoracic aortic aneurysm.
MRA may be preferable to CT over the long term to limit radiation exposure.2 Echocardiography should be used if the aortic root or ascending aorta is well visualized, but in most patients the view of the mid to distal ascending aorta is limited. Echocardiography also offers evaluation of left ventricular size and function and allows for follow-up of aortic valve disease.

Our flow chart of initial screening and follow-up is shown in Figure 5.

Screening of family members

In our center, we routinely recommend screening of all first-degree relatives of patients with TAA. Aortic imaging with echocardiography plus CT or MRI should be considered to detect asymptomatic disease.2 In patients with a strong family history (ie, multiple relatives affected with aortic aneurysm, dissection, or sudden cardiac death), genetic screening and testing for known mutations are recommended for the patient as well as for the family members.

If a mutation is identified in a family, then first-degree relatives should undergo genetic screening for the mutation and aortic imaging.2 Imaging in second-degree relatives may also be considered if one or more first-degree relatives are found to have aortic dilation.2

We recommend similar screening of first-degree family members of patients with bicuspid aortic valve aortopathy. In patients with young children, we recommend obtaining an echocardiogram of the child to look for a bicuspid aortic valve or aortic dilation. If an abnormality is detected or suspected, dedicated imaging with MRA to assess aortic dimensions is warranted.

BACK TO OUR PATIENT WITH A BICUSPID AORTIC VALVE

Our patient with a bicuspid aortic valve had a 4.6-cm root, an ascending aortic aneurysm, and several affected family members.

We would obtain dedicated aortic imaging at this patient’s initial visit with either gated CT with contrast or MRA, and we would obtain a cardioaortic surgery consult. We would repeat these studies at a follow-up visit 6 months later to detect any aortic growth compared with initial studies, and follow up annually thereafter. Echocardiography can also be done at the initial visit to determine if valvular disease is present that may influence clinical decisions.

Surgery would likely be recommended once the root reached a maximum area-to-height ratio greater than 10 cm2/m, or if the valve became severely dysfunctional during follow-up.

BACK TO OUR PATIENT WITH MARFAN SYNDROME

The young woman with Marfan syndrome has a 4.6-cm aortic root aneurysm and 2+ aortic insufficiency. Her question pertains to the threshold at which an operation would be considered. This question is complicated and is influenced by several concurrent clinical features in her presentation.

Starting with size criteria, patients with Marfan syndrome should be considered for elective aortic root repair at a diameter greater than 5 cm. However, an aortic cross-sectional area-to-height ratio greater than 10 cm2/m may provide a more robust metric for clinical decision-making than aortic diameter alone. Additional factors such as degree of aortic insufficiency and deleterious left ventricular remodeling may urge one to consider aortic root repair at a diameter of 4.5 cm.

These factors, including rate of growth and the surgeon’s assessment about his or her ability to preserve the aortic valve during repair, should be considered collectively in this scenario.

Thoracic aortic aneurysm (TAA) needs to be detected, monitored, and managed in a timely manner to prevent a serious consequence such as acute dissection or rupture. But only about 5% of patients experience symptoms before an acute event occurs, and for the other 95% the first “symptom” is often death.1 Most cases are detected either incidentally with echocardiography, computed tomography (CT), or magnetic resonance imaging (MRI) during workup for another condition. Patients may also be diagnosed during workup of a murmur or after a family member is found to have an aneurysm. Therefore, its true incidence is difficult to determine.2

With these facts in mind, how would you manage the following 2 cases?

Case 1: Bicuspid aortic valve, ascending aortic aneurysm

A 45-year-old man with stage 1 hypertension presents for evaluation of a bicuspid aortic valve and ascending aortic aneurysm. He has several first-degree relatives with similar conditions, and his brother recently underwent elective aortic repair. At the urging of his primary care physician, he underwent screening echocardiography, which demonstrated a “dilated root and ascending aorta” 4.6 cm in diameter. He presents today to discuss management options and how the aneurysm could affect his everyday life.

Case 2: Marfan syndrome in a young woman

A 24-year-old woman with Marfan syndrome diagnosed in adolescence presents for annual follow-up. She has many family members with the same condition, and several have undergone prophylactic aortic root repair. Her aortic root has been monitored annually for progression of dilation, and today it is 4.6 cm in diameter, a 3-mm increase from the last measurement. She has grade 2+ aortic insufficiency (on a scale of 1+ to 4+) based on echocardiography, but she has no symptoms. She is curious about what size her aortic root will need to reach for surgery to be considered.

LIKELY UNDERDETECTED

TAA is being detected more often than in the past thanks to better detection methods and heightened awareness among physicians and patients. While an incidence rate of 10.4 per 100,000 patient-years is often cited,3 this figure likely underestimates the true incidence of this clinically silent condition. The most robust data come from studies based on in-hospital diagnostic codes coupled with data from autopsies for out-of-hospital deaths.

Olsson et al,4 in a 2016 study in Sweden, found the incidence of TAA and aortic dissection to be 16.3 per 100,000 per year for men and 9.1 per 100,000 per year for women.

Clouse et al5 reported the incidence of thoracic aortic dissection as 3.5 per 100,000 patient-years, and the same figure for thoracic aortic rupture. 

Aneurysmal disease accounts for 52,000 deaths per year in the United States, making it the 19th most common cause of death.6 These figures are likely lower than the true mortality rate for this condition, given that aortic dissection is often mistaken for acute myocardial infarction or other acute event if an autopsy is not done to confirm the cause of death.7

RISK FACTORS FOR THORACIC AORTIC ANEURYSM

Risk factors for TAA include genetic conditions that lead to aortic medial weakness or destruction such as Loeys-Dietz syndrome and Marfan syndrome.2 In addition, family history is important even in the absence of known genetic mutations. Other risk factors include conditions that increase aortic wall stress, such as hypertension, cocaine abuse, extreme weightlifting, trauma, and aortic coarctation.2

DIAMETER INCREASES WITH AGE, BODY SURFACE AREA

Figure 1.
Figure 1.
The thoracic aorta consists of the root and the ascending, arch, and descending segments (Figure 1); the abdominal aorta consists of the suprarenal and infrarenal segments.8,9 These divisions are useful, as aneurysmal disease can be confined to specific locations along the length of the vessel, and the location can affect the clinical presentation and management decisions and lend insight into the pathogenesis.

Normal dimensions for the aortic segments differ depending on age, sex, and body surface area.8,44,45 The size of the aortic root may also vary depending on how it is measured, due to the root’s trefoil shape. Measured sinus to sinus, the root is larger than when measured sinus to commissure on CT angiography or cardiac MRI. It is also larger when measured leading edge to leading edge than inner edge to inner edge on echocardiography.10

TAA is defined as an aortic diameter at least 50% greater than the upper limit of normal.8 

Aortic diameters: Upper limits of normal
The aorta increases in diameter by 0.7 to 1.9 mm per year if not dilated, and larger-diameter aortas grow faster.11 In addition, men have a larger aortic diameter than women.10 Size-based criteria and indices are useful for defining and monitoring aneurysmal progression, since larger patients tend to have a larger aorta.10  Table 1 lists upper limits of normal values for the ascending and descending aorta by age, sex, and body surface area obtained by Wolak et al in a study using noncontrast CT.10

Geometric changes in the curvature of the ascending aorta, aortic arch, and descending thoracic aorta can occur as the result of hypertension, atherosclerosis, or connective tissue disease. 

 

 

HOW IS TAA DIAGNOSED?

Table 2: Common causes of thoracic aortic aneurysm
TAA is asymptomatic in most patients and is usually detected on imaging. However, it should be actively looked for in patients who have a family history of Marfan, Loeys-Dietz, or Ehlers-Danlos syndrome or a family history of aortic aneurysm or dissection (not necessarily in a first-degree relative, but more significant in a first-degree relative or in multiple family members across generations), and in patients with a bicuspid aortic valve or autoimmune disease such as Takayasu or giant cell arteritis (Table 2). Table 3 lists the common genetic disorders with their associated mutations and clinical features.

Table 3: Inherited connective tissue diseases and thoracic aortic aneurysm
Some patients present with chest pain that may be related to local compression due to the aorta’s large size. Hoarseness, dysphagia, or chronic cough may be a presenting symptom, particularly in patients with descending aortic aneurysm or congenital aortic anomaly.

Table 4: Imaging studies for aortic aneurysm
An abnormal chest radiograph with a prominent aortic shadow or mediastinal widening should prompt further evaluation for TAA. In addition, patients with known abdominal aortic aneurysm should have the rest of the aorta imaged as well to rule out associated TAA.

Imaging tests

Figure 2. Echocardiographic image of an aneurysmal aortic root (white arrow) that tapers to normal dimensions at the sinotubular junction (yellow arrow) and ascending aorta.
Figure 2. Echocardiographic image of an aneurysmal aortic root (white arrow) that tapers to normal dimensions at the sinotubular junction (yellow arrow) and ascending aorta.
TAA can be diagnosed with several imaging tests, each with advantages and disadvantages (Table 4).12 Most commonly used in its diagnosis and follow-up are transthoracic echocardiography (Figure 2 [video 1, video 2]), cardiac-gated computed tomographic angiography (CTA), and MRI (Figure 3 [video 3, video 4, video 5]). Transesophageal echocardiography is not routinely used in diagnosing TAA but is invaluable during surgery to assess aortic valve function and immediate results of aortic repair.

Figure 3. An aortic root aneurysm in a patient with Marfan syndrome using magnetic resonance angiography.
Figure 3. An aortic root aneurysm in a patient with Marfan syndrome using magnetic resonance angiography.
Which imaging test to use depends on the clinical context as well as the availability and expertise at each institution. For example, screening of first-degree relatives of a patient with thoracic aortic disease typically begins with transthoracic echocardiography and can be escalated to CTA or MRI if an abnormality is detected. Alternatively, patients with connective tissue disease with a particularly severe vascular phenotype such as Loeys-Dietz syndrome should undergo screening with dedicated aortic imaging such as CTA, since this disease can affect the entire aorta and its branch vessels.

Figure 4. Top, 3D reconstruction of an ascending aortic aneurysm in a patient with a bicuspid aortic valve. Bottom, 3D reconstruction of a young patient with an aortic root aneurysm.
Figure 4. Top, 3D reconstruction of an ascending aortic aneurysm in a patient with a bicuspid aortic valve. Bottom, 3D reconstruction of a young patient with an aortic root aneurysm. Note the tapering from the aneurysmal aortic root to the normal-sized ascending aorta. LMCA = left main coronary artery; RCA = right coronary artery.
The aortic diameter should be measured perpendicularly to the centerline of flow, which is now easier with dedicated aortic imaging technology and widely available, user-friendly, 3-dimensional reconstruction software (Figure 4 [video 6]).2

It is particularly important to obtain a gated CTA image in patients with aortic root aneurysm to avoid motion artifact and possible erroneous measurements. Gated CTA is done with electrocardiographic synchronization and allows for image processing to correct for cardiac motion.

 

 

HOW IS TAA CLASSIFIED?

TAA can be caused by a variety of inherited and sporadic conditions. These differences in pathogenesis lend themselves to classification of aneurysms into groups. Table 3 highlights the most common conditions associated with TAA.13

Bicuspid aortic valve aortopathy

From 1% to 2% of people have a bicuspid aortic valve, with a 3-to-1 male predominance.14,15 Aortic dilation occurs in 35% to 80% of people who have a bicuspid aortic valve, conferring a risk of dissection 8 times higher than in the general population.16–18

The pathogenic mechanisms that lead to this condition are widely debated, although a combination of genetic defects leading to intrinsic weakening of the aortic wall and hemodynamic effects likely contribute.19 Evidence of hemodynamic contributions to aortic dilation comes from findings that particular patterns of cusp fusion of the bicuspid aortic valve result in changes in transvalvular flow, placing more stress on specific regions of the ascending aorta.20,21 These hemodynamic alterations result in patterns of aortic dilation that depend on cusp fusion and the presence of valvular disease.

Multiple small studies found that replacing bicuspid aortic valves reduced the rate of aortic dilation, suggesting that hemodynamic factors may play a larger role than intrinsic wall properties in genetically susceptible individuals.22,23 However, larger studies are needed before any definitive conclusions can be made.

HOW IS ANEURYSM MANAGED ON AN OUTPATIENT BASIS?

Patients with a new diagnosis of TAA should be referred to a cardiologist with expertise in managing aortic disease or to a cardiac surgeon specializing in aortic surgery, depending on the initial size of the aneurysm.

Control blood pressure with beta-blockers

Medical management for patients with TAA has historically been limited to strict blood pressure control aimed at reducing aortic wall stress, mainly with beta-blockers.

Are angiotensin II receptor blockers (ARBs) beneficial? Studies in a mouse model of Marfan syndrome revealed that the ARB losartan attenuated aortic root growth.24 The results of early, small studies in humans were promising,25–27 but larger randomized trials have shown no advantage of losartan over beta-blockers in slowing aortic root growth.28 These negative results led many to question the effectiveness of losartan, although some point out that no studies have shown even beta-blockers to be beneficial in reducing the clinical end points of death or dissection.29 On the other hand, patients with certain FBN1 mutations respond more readily than others to losartan.30 Additional clinical trials of ARBs in Marfan syndrome are ongoing.

Current guidelines recommend stringent blood pressure control and smoking cessation for patients with a small aneurysm not requiring surgery and for those who are considered unsuitable for surgical or percutaneous intervention (level of evidence C, the lowest).2 For patients with TAA, it is considered reasonable to give beta-blockers. Angiotensin-converting enzyme inhibitors or ARBs may be used in combination with beta-blockers, titrated to the lowest tolerable blood pressure without adverse effects (level of evidence B).2

The recommended target blood pressure is less than 140/90 mm Hg, or 130/80 mm Hg in those with diabetes or chronic kidney disease (level of evidence B).2 However, we recommend more stringent blood pressure control: ie, less than 130/80 mm Hg for all patients with aortic aneurysm and a heart rate goal of 70 beats per minute or less, as tolerated.

Activity restriction

Activity restrictions for patients with TAA are largely based on theory, and certain activities may require more modification than others. For example, heavy lifting should be discouraged, as it may increase blood pressure significantly for short periods of time.2,31 The increased wall stress, in theory, could initiate dissection or rupture. However, moderate-intensity aerobic activity is rarely associated with significant elevations in blood pressure and should be encouraged. Stressful emotional states have been anecdotally associated with aortic dissection; thus, measures to reduce stress may offer some benefit.31

Our recommendations. While there are no published guidelines regarding activity restrictions in patients with TAA, we use a graded approach based on aortic diameter:

  • 4.0 to 4.4 cm—lift no more than 75 pounds
  • 4.5 to 5 cm—lift no more than 50 pounds
  • 5 cm—lift no more than 25 pounds.

We also recommend not lifting anything heavier than half of one’s body weight and to avoid breath-holding or performing the Valsalva maneuver while lifting. Although these recommendations are somewhat arbitrary, based on theory and a large clinical experience at our aortic center, they seem reasonable and practical.

Activity restrictions should be stringent and individualized in patients with Marfan, Loeys-Dietz, or Ehlers-Danlos syndrome due to increased risk of dissection or rupture even if the aorta is normal in size.

We sometimes recommend exercise stress testing to assess the heart rate and blood pressure response to exercise, and we are developing research protocols to help tailor activity recommendations.

 

 

WHEN SHOULD A PATIENT BE REFERRED?

To a cardiologist at the time of diagnosis

As soon as TAA is diagnosed, the patient should be referred to a cardiologist who has special interest in aortic disease. This will allow for appropriate and timely decisions about medical management, imaging, follow-up, and referral to surgery. Additional recommendations for screening of family members and referral to clinical geneticists can be discussed at this juncture. Activity restrictions should be reviewed at the initial evaluation.

To a surgeon relatively early

Size thresholds for surgical intervention are discussed below, but one should not wait until these thresholds are reached to send the patient for surgical consultation. It is beneficial to the state of mind of a potential surgical candidate to have early discussions pertaining to the types of operations available, their outcomes, and associated risks and benefits. If a patient’s aortic size remains stable over time, he or she may be followed by the cardiologist until significant size or growth has been documented, at which time the patient and surgeon can reconvene to discuss options for definitive treatment.

To a clinical geneticist

If 1 or more first-degree relatives of a patient with TAA or dissection are found to have aneurysmal disease, referral to a clinical geneticist is very important for genetic testing of multiple genes that have been implicated in thoracic aortic aneurysm and dissection.

WHEN SHOULD TAA BE REPAIRED?

Surgery to prevent rupture or dissection remains the definitive treatment of TAA when size thresholds are reached, and symptomatic aneurysm should be operated on regardless of the size. However, rarely are thoracic aneurysms symptomatic unless they rupture or dissect. The size criteria are based on underlying genetic etiology if known and on the behavior and natural course of TAA.

Size and other factors

Treatment should be tailored to the patient’s clinical scenario, family history, and estimated risk of rupture or dissection, balanced against the individual center’s outcomes of elective aortic replacement.32 For example, young and otherwise healthy patients with TAA and a family history of aortic dissection (who may be more likely to have connective tissue disorders such as Marfan syndrome, Loeys-Dietz syndrome, or vascular Ehler-Danlos syndrome) may elect to undergo repair when the aneurysm reaches or nearly reaches the diameter of that of the family member’s aorta when dissection occurred.2 On the other hand, TAA of degenerative etiology (eg, related to smoking or hypertension) measuring less than 5.5 cm in an older patient with comorbidities poses a lower risk of a catastrophic event such as dissection or rupture than the risk of surgery.11

Thresholds for surgery. Once the diameter of the ascending aorta reaches 6 cm, the likelihood of an acute dissection is 31%.11 A similar threshold is reached for the descending aorta at a size of 7 cm.11 Therefore, to avoid high-risk emergency surgery on an acutely dissected aorta, surgery on an ascending aortic aneurysm of degenerative etiology is usually suggested when the aneurysm reaches 5.5 cm or a documented growth rate greater than 0.5 cm/year.2,33

Additionally, in patients already undergoing surgery for valvular or coronary disease, prophylactic aortic replacement is recommended if the ascending aorta is larger than 4.5 cm. The threshold for intervention is lower in patients with connective tissue disease (> 5.0 cm for Marfan syndrome, 4.4–4.6 cm for Loeys-Dietz syndrome).2,33

Observational studies suggest that the risk of aortic complications in patients with bicuspid aortic valve aortopathy is low overall, though significantly greater than in the general population.18,34,35 These findings led to changes in the 2014 American College of Cardiology/American Heart Association guidelines on valvular heart disease,36 suggesting a surgical threshold of 5.5 cm in the absence of significant valve disease or family history of dissection of an aorta of smaller diameter.

A 2015 study of dissection risk in patients with bicuspid aortic valve aortopathy by our group found a dramatic increase in risk of aortic dissection for ascending aortic diameters greater than 5.3 cm, and a gradual increase in risk for aortic root diameters greater than 5.0 cm.37 In addition, a near-constant 3% to 4% risk of dissection was present for aortic diameters ranging from 4.7 cm to 5.0 cm, revealing that watchful waiting carries its own inherent risks.37 In our surgical experience with this population, the hospital mortality rate and risk of stroke from aortic surgery were 0.25% and 0.75%, respectively.37 Thus, the decision to operate for aortic aneurysm in the setting of a bicuspid aortic valve should take into account patient-specific factors and institutional outcomes.

A statement of clarification in the American College of Cardiology/American Heart Association guidelines was published in 2015, recommending surgery for patients with an aortic diameter of 5.0 cm or greater if the patient is at low risk and the surgery is performed by an experienced surgical team at a center with established surgical expertise in this condition.38 However, current recommendations are for surgery at 5.5 cm if the above conditions are not met.

Ratio of aortic cross-sectional area to height

Although size alone has long been used to guide surgical intervention, a recent review from the International Registry of Aortic Dissection revealed that 59% of patients suffered aortic dissection at diameters less than 5.5 cm, and that patients with certain connective tissue diseases such as Loeys-Dietz syndrome or familial thoracic aneurysm and dissection had a documented propensity for dissection at smaller diameters.39–41

Size indices such as the aortic cross-sectional area indexed to height have been implemented in guidelines for certain patient populations (eg, 10 cm2/m in Marfan syndrome) and provide better risk stratification than size cutoffs alone.2,42

The ratio of aortic cross-sectional area to the patient’s height has also been applied to patients with bicuspid aortic valve-associated aortopathy and to those with a dilated aorta and a tricuspid aortic valve.43,44 Notably, a ratio greater than 10 cm2/m has been associated with aortic dissection in these groups, and this cutoff provides better stratification for prediction of death than traditional size metrics.27,28

 

 

HOW SHOULD PATIENTS BE SCREENED? WHAT FOLLOW-UP IS NECESSARY?

Initial screening and follow-up

Follow-up of TAA depends on the initial aortic size or rate of growth, or both. For patients presenting for the first time with TAA, it is reasonable to obtain definitive aortic imaging with CT or magnetic resonance angiography (MRA), then to repeat imaging at 6 months to document stability. If the aortic dimensions remain stable, then annual follow-up with CT or MRA is reasonable.2

Figure 5. Initial screening and follow-up of thoracic aortic aneurysm.
Figure 5. Initial screening and follow-up of thoracic aortic aneurysm.
MRA may be preferable to CT over the long term to limit radiation exposure.2 Echocardiography should be used if the aortic root or ascending aorta is well visualized, but in most patients the view of the mid to distal ascending aorta is limited. Echocardiography also offers evaluation of left ventricular size and function and allows for follow-up of aortic valve disease.

Our flow chart of initial screening and follow-up is shown in Figure 5.

Screening of family members

In our center, we routinely recommend screening of all first-degree relatives of patients with TAA. Aortic imaging with echocardiography plus CT or MRI should be considered to detect asymptomatic disease.2 In patients with a strong family history (ie, multiple relatives affected with aortic aneurysm, dissection, or sudden cardiac death), genetic screening and testing for known mutations are recommended for the patient as well as for the family members.

If a mutation is identified in a family, then first-degree relatives should undergo genetic screening for the mutation and aortic imaging.2 Imaging in second-degree relatives may also be considered if one or more first-degree relatives are found to have aortic dilation.2

We recommend similar screening of first-degree family members of patients with bicuspid aortic valve aortopathy. In patients with young children, we recommend obtaining an echocardiogram of the child to look for a bicuspid aortic valve or aortic dilation. If an abnormality is detected or suspected, dedicated imaging with MRA to assess aortic dimensions is warranted.

BACK TO OUR PATIENT WITH A BICUSPID AORTIC VALVE

Our patient with a bicuspid aortic valve had a 4.6-cm root, an ascending aortic aneurysm, and several affected family members.

We would obtain dedicated aortic imaging at this patient’s initial visit with either gated CT with contrast or MRA, and we would obtain a cardioaortic surgery consult. We would repeat these studies at a follow-up visit 6 months later to detect any aortic growth compared with initial studies, and follow up annually thereafter. Echocardiography can also be done at the initial visit to determine if valvular disease is present that may influence clinical decisions.

Surgery would likely be recommended once the root reached a maximum area-to-height ratio greater than 10 cm2/m, or if the valve became severely dysfunctional during follow-up.

BACK TO OUR PATIENT WITH MARFAN SYNDROME

The young woman with Marfan syndrome has a 4.6-cm aortic root aneurysm and 2+ aortic insufficiency. Her question pertains to the threshold at which an operation would be considered. This question is complicated and is influenced by several concurrent clinical features in her presentation.

Starting with size criteria, patients with Marfan syndrome should be considered for elective aortic root repair at a diameter greater than 5 cm. However, an aortic cross-sectional area-to-height ratio greater than 10 cm2/m may provide a more robust metric for clinical decision-making than aortic diameter alone. Additional factors such as degree of aortic insufficiency and deleterious left ventricular remodeling may urge one to consider aortic root repair at a diameter of 4.5 cm.

These factors, including rate of growth and the surgeon’s assessment about his or her ability to preserve the aortic valve during repair, should be considered collectively in this scenario.

References
  1. Elefteriades JA, Farkas EA. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol 2010; 55(9):841–857. doi:10.1016/j.jacc.2009.08.084
  2. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. Anesth Analg 2010; 111(2):279–315. doi:10.1213/ANE.0b013e3181dd869b
  3. Clouse WD, Hallett JW Jr, Schaff HV, Gayari MM, Ilstrup DM, Melton LJ 3rd. Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA 1998; 280(22):1926–1929. pmid:9851478
  4. Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation 2006; 114(24):2611–2618. doi:10.1161/CIRCULATIONAHA.106.630400
  5. Clouse WD, Hallett JW Jr, Schaff HV, et al. Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture. Mayo Clin Proc 2004; 79(2):176–180. pmid:14959911
  6. US Centers for Disease Control and Prevention (CDC). National Center for Injury Prevention and Control. WISQARS leading causes of death reports, 1999 – 2007. https://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html. Accessed May 21, 2018.
  7. Hansen MS, Nogareda GJ, Hutchison SJ. Frequency of and inappropriate treatment of misdiagnosis of acute aortic dissection. Am J Cardiol 2007; 99(6):852–856. doi:10.1016/j.amjcard.2006.10.055
  8. Goldfinger JZ, Halperin JL, Marin ML, Stewart AS, Eagle KA, Fuster V. Thoracic aortic aneurysm and dissection. J Am Coll Cardiol 2014; 64(16):1725–1739. doi:10.1016/j.jacc.2014.08.025
  9. Kumar V, Abbas A, Aster J. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA: Elsevier/Saunders; 2015.
  10. Wolak A, Gransar H, Thomson LE, et al. Aortic size assessment by noncontrast cardiac computed tomography: normal limits by age, gender, and body surface area. JACC Cardiovasc Imaging 2008; 1(2):200–209. doi:10.1016/j.jcmg.2007.11.005
  11. Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg 2002; 74(5):S1877–S1880; discussion S1892–S1898. pmid:12440685
  12. Smith AD, Schoenhagen P. CT imaging for acute aortic syndrome. Cleve Clin J Med 2008; 75(1):7–17. pmid:18236724
  13. Cury M, Zeidan F, Lobato AC. Aortic disease in the young: genetic aneurysm syndromes, connective tissue disorders, and familial aortic aneurysms and dissections. Int J Vasc Med 2013(2013); 2013:267215. doi:10.1155/2013/267215
  14. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39(12):1890–1900. doi:10.1016/S0735-1097(02)01886-7
  15. Fedak PW, Verma S, David TE, Leask RL, Weisel RD, Butany J. Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation 2002; 106(8):900–904. pmid:12186790
  16. Della Corte A, Bancone C, Quarto C, et al. Predictors of ascending aortic dilatation with bicuspid aortic valve: a wide spectrum of disease expression. Eur J Cardiothorac Surg 2007; 31(3):397–405. doi:10.1016/j.ejcts.2006.12.006
  17. Jackson V, Petrini J, Caidahl K, et al. Bicuspid aortic valve leaflet morphology in relation to aortic root morphology: a study of 300 patients undergoing open-heart surgery. Eur J Cardiothorac Surg 2011; 40(3):e118–e124. doi:10.1016/j.ejcts.2011.04.014
  18. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011; 306(10):1104–1112. doi:10.1001/jama.2011.1286
  19. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med 2014; 370(20):1920–1929. doi:10.1056/NEJMra1207059
  20. Barker AJ, Markl M, Bürk J, et al. Bicuspid aortic valve is associated with altered wall shear stress in the ascending aorta. Circ Cardiovasc Imaging 2012; 5(4):457–466. doi:10.1161/CIRCIMAGING.112.973370
  21. Hope MD, Hope TA, Meadows AK, et al. Bicuspid aortic valve: four-dimensional MR evaluation of ascending aortic systolic flow patterns. Radiology 2010; 255(1):53–61. doi:10.1148/radiol.09091437
  22. Abdulkareem N, Soppa G, Jones S, Valencia O, Smelt J, Jahangiri M. Dilatation of the remaining aorta after aortic valve or aortic root replacement in patients with bicuspid aortic valve: a 5-year follow-up. Ann Thorac Surg 2013; 96(1):43–49. doi:10.1016/j.athoracsur.2013.03.086
  23. Regeer MV, Versteegh MI, Klautz RJ, et al. Effect of aortic valve replacement on aortic root dilatation rate in patients with bicuspid and tricuspid aortic valves. Ann Thorac Surg 2016; 102(6):1981–1987. doi:10.1016/j.athoracsur.2016.05.038
  24. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312(5770):117–121. doi:10.1126/science.1124287
  25. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med 2008; 358(26):2787–2795. doi:10.1056/NEJMoa0706585
  26. Chiu HH, Wu MH, Wang JK, et al. Losartan added to ß-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc 2013; 88(3):271–276. doi:10.1016/j.mayocp.2012.11.005
  27. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013; 34(45):3491–3500. doi:10.1093/eurheartj/eht334
  28. Lacro RV, Dietz HC, Sleeper LA, et al; Pediatric Heart Network Investigators. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med 2014; 371(22):2061–2071. doi:10.1056/NEJMoa1404731
  29. Ziganshin BA, Mukherjee SK, Elefteriades JA, et al. Atenolol versus losartan in Marfan’s syndrome (letters). N Engl J Med 2015; 372(10):977–981. doi:10.1056/NEJMc1500128
  30. Franken R, den Hartog AW, Radonic T, et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ Cardiovasc Genet 2015; 8(2):383–388. doi:10.1161/CIRCGENETICS.114.000950
  31. Elefteriades JA. Thoracic aortic aneurysm: reading the enemy’s playbook. Curr Probl Cardiol 2008; 33(5):203–277. doi:10.1016/j.cpcardiol.2008.01.004
  32. Idrees JJ, Roselli EE, Lowry AM, et al. Outcomes after elective proximal aortic replacement: a matched comparison of isolated versus multicomponent operations. Ann Thorac Surg 2016; 101(6):2185–2192. doi:10.1016/j.athoracsur.2015.12.026
  33. Hiratzka LF, Creager MA, Isselbacher EM, et al. Surgery for aortic dilatation in patients with bicuspid aortic valves: a statement of clarification from the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 2016; 151(4):959–966. doi:10.1016/j.jtcvs.2015.12.001
  34. Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid aortic valves. JAMA 2008; 300(11):1317–1325. doi:10.1001/jama.300.11.1317
  35. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002; 73(1):17–28. pmid:11834007
  36. Nishimura RA, Otto CM, Bono RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American heart Association Task Force on Practice Guidelines. Circulation 2014; 129(23):2440–2492. doi:10.1161/CIR.0000000000000029
  37. Wojnarski CM, Svensson LG, Roselli EE, et al. Aortic dissection in patients with bicuspid aortic valve–associated aneurysms. Ann Thorac Surg 2015; 100(5):1666–1674. doi:10.1016/j.athoracsur.2015.04.126
  38. Hiratzka LF, Creager MA, Isselbacher EM, et al. Surgery for aortic dilatation in patients with bicuspid aortic valves: a statement of clarification from the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016; 133(7):680–686. doi:10.1161/CIR.0000000000000331
  39. Pape LA, Tsai TT, Isselbacher EM, et al; International Registry of Acute Aortic Dissection (IRAD) Investigators. Aortic diameter > or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2007; 116(10):1120–1127. doi:10.1161/CIRCULATIONAHA.107.702720
  40. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006; 355(8):788–798. doi:10.1056/NEJMoa055695
  41. Guo DC, Pannu H, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 2007; 39(12):1488–1493. doi:10.1038/ng.2007.6
  42. Svensson LG, Khitin L. Aortic cross-sectional area/height ratio timing of aortic surgery in asymptomatic patients with Marfan syndrome. J Thorac Cardiovasc Surg 2002; 123(2):360–361. pmid:11828302
  43. Svensson LG, Kim KH, Lytle BW, Cosgrove DM. Relationship of aortic cross-sectional area to height ratio and the risk of aortic dissection in patients with bicuspid aortic valves. J Thorac Cardiovasc Surg 2003; 126(3):892–893. pmid:14502185
  44. Masri A, Kalahasti V, Svensson LG, et al. Aortic cross-sectional area/height ratio and outcomes in patients with a trileaflet aortic valve and a dilated aorta. Circulation 2016; 134(22):1724–1737. doi:10.1161/CIRCULATIONAHA.116.022995
References
  1. Elefteriades JA, Farkas EA. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol 2010; 55(9):841–857. doi:10.1016/j.jacc.2009.08.084
  2. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. Anesth Analg 2010; 111(2):279–315. doi:10.1213/ANE.0b013e3181dd869b
  3. Clouse WD, Hallett JW Jr, Schaff HV, Gayari MM, Ilstrup DM, Melton LJ 3rd. Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA 1998; 280(22):1926–1929. pmid:9851478
  4. Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation 2006; 114(24):2611–2618. doi:10.1161/CIRCULATIONAHA.106.630400
  5. Clouse WD, Hallett JW Jr, Schaff HV, et al. Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture. Mayo Clin Proc 2004; 79(2):176–180. pmid:14959911
  6. US Centers for Disease Control and Prevention (CDC). National Center for Injury Prevention and Control. WISQARS leading causes of death reports, 1999 – 2007. https://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html. Accessed May 21, 2018.
  7. Hansen MS, Nogareda GJ, Hutchison SJ. Frequency of and inappropriate treatment of misdiagnosis of acute aortic dissection. Am J Cardiol 2007; 99(6):852–856. doi:10.1016/j.amjcard.2006.10.055
  8. Goldfinger JZ, Halperin JL, Marin ML, Stewart AS, Eagle KA, Fuster V. Thoracic aortic aneurysm and dissection. J Am Coll Cardiol 2014; 64(16):1725–1739. doi:10.1016/j.jacc.2014.08.025
  9. Kumar V, Abbas A, Aster J. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA: Elsevier/Saunders; 2015.
  10. Wolak A, Gransar H, Thomson LE, et al. Aortic size assessment by noncontrast cardiac computed tomography: normal limits by age, gender, and body surface area. JACC Cardiovasc Imaging 2008; 1(2):200–209. doi:10.1016/j.jcmg.2007.11.005
  11. Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg 2002; 74(5):S1877–S1880; discussion S1892–S1898. pmid:12440685
  12. Smith AD, Schoenhagen P. CT imaging for acute aortic syndrome. Cleve Clin J Med 2008; 75(1):7–17. pmid:18236724
  13. Cury M, Zeidan F, Lobato AC. Aortic disease in the young: genetic aneurysm syndromes, connective tissue disorders, and familial aortic aneurysms and dissections. Int J Vasc Med 2013(2013); 2013:267215. doi:10.1155/2013/267215
  14. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39(12):1890–1900. doi:10.1016/S0735-1097(02)01886-7
  15. Fedak PW, Verma S, David TE, Leask RL, Weisel RD, Butany J. Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation 2002; 106(8):900–904. pmid:12186790
  16. Della Corte A, Bancone C, Quarto C, et al. Predictors of ascending aortic dilatation with bicuspid aortic valve: a wide spectrum of disease expression. Eur J Cardiothorac Surg 2007; 31(3):397–405. doi:10.1016/j.ejcts.2006.12.006
  17. Jackson V, Petrini J, Caidahl K, et al. Bicuspid aortic valve leaflet morphology in relation to aortic root morphology: a study of 300 patients undergoing open-heart surgery. Eur J Cardiothorac Surg 2011; 40(3):e118–e124. doi:10.1016/j.ejcts.2011.04.014
  18. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011; 306(10):1104–1112. doi:10.1001/jama.2011.1286
  19. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med 2014; 370(20):1920–1929. doi:10.1056/NEJMra1207059
  20. Barker AJ, Markl M, Bürk J, et al. Bicuspid aortic valve is associated with altered wall shear stress in the ascending aorta. Circ Cardiovasc Imaging 2012; 5(4):457–466. doi:10.1161/CIRCIMAGING.112.973370
  21. Hope MD, Hope TA, Meadows AK, et al. Bicuspid aortic valve: four-dimensional MR evaluation of ascending aortic systolic flow patterns. Radiology 2010; 255(1):53–61. doi:10.1148/radiol.09091437
  22. Abdulkareem N, Soppa G, Jones S, Valencia O, Smelt J, Jahangiri M. Dilatation of the remaining aorta after aortic valve or aortic root replacement in patients with bicuspid aortic valve: a 5-year follow-up. Ann Thorac Surg 2013; 96(1):43–49. doi:10.1016/j.athoracsur.2013.03.086
  23. Regeer MV, Versteegh MI, Klautz RJ, et al. Effect of aortic valve replacement on aortic root dilatation rate in patients with bicuspid and tricuspid aortic valves. Ann Thorac Surg 2016; 102(6):1981–1987. doi:10.1016/j.athoracsur.2016.05.038
  24. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312(5770):117–121. doi:10.1126/science.1124287
  25. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med 2008; 358(26):2787–2795. doi:10.1056/NEJMoa0706585
  26. Chiu HH, Wu MH, Wang JK, et al. Losartan added to ß-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc 2013; 88(3):271–276. doi:10.1016/j.mayocp.2012.11.005
  27. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 2013; 34(45):3491–3500. doi:10.1093/eurheartj/eht334
  28. Lacro RV, Dietz HC, Sleeper LA, et al; Pediatric Heart Network Investigators. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med 2014; 371(22):2061–2071. doi:10.1056/NEJMoa1404731
  29. Ziganshin BA, Mukherjee SK, Elefteriades JA, et al. Atenolol versus losartan in Marfan’s syndrome (letters). N Engl J Med 2015; 372(10):977–981. doi:10.1056/NEJMc1500128
  30. Franken R, den Hartog AW, Radonic T, et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ Cardiovasc Genet 2015; 8(2):383–388. doi:10.1161/CIRCGENETICS.114.000950
  31. Elefteriades JA. Thoracic aortic aneurysm: reading the enemy’s playbook. Curr Probl Cardiol 2008; 33(5):203–277. doi:10.1016/j.cpcardiol.2008.01.004
  32. Idrees JJ, Roselli EE, Lowry AM, et al. Outcomes after elective proximal aortic replacement: a matched comparison of isolated versus multicomponent operations. Ann Thorac Surg 2016; 101(6):2185–2192. doi:10.1016/j.athoracsur.2015.12.026
  33. Hiratzka LF, Creager MA, Isselbacher EM, et al. Surgery for aortic dilatation in patients with bicuspid aortic valves: a statement of clarification from the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 2016; 151(4):959–966. doi:10.1016/j.jtcvs.2015.12.001
  34. Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid aortic valves. JAMA 2008; 300(11):1317–1325. doi:10.1001/jama.300.11.1317
  35. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002; 73(1):17–28. pmid:11834007
  36. Nishimura RA, Otto CM, Bono RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American heart Association Task Force on Practice Guidelines. Circulation 2014; 129(23):2440–2492. doi:10.1161/CIR.0000000000000029
  37. Wojnarski CM, Svensson LG, Roselli EE, et al. Aortic dissection in patients with bicuspid aortic valve–associated aneurysms. Ann Thorac Surg 2015; 100(5):1666–1674. doi:10.1016/j.athoracsur.2015.04.126
  38. Hiratzka LF, Creager MA, Isselbacher EM, et al. Surgery for aortic dilatation in patients with bicuspid aortic valves: a statement of clarification from the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016; 133(7):680–686. doi:10.1161/CIR.0000000000000331
  39. Pape LA, Tsai TT, Isselbacher EM, et al; International Registry of Acute Aortic Dissection (IRAD) Investigators. Aortic diameter > or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2007; 116(10):1120–1127. doi:10.1161/CIRCULATIONAHA.107.702720
  40. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006; 355(8):788–798. doi:10.1056/NEJMoa055695
  41. Guo DC, Pannu H, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 2007; 39(12):1488–1493. doi:10.1038/ng.2007.6
  42. Svensson LG, Khitin L. Aortic cross-sectional area/height ratio timing of aortic surgery in asymptomatic patients with Marfan syndrome. J Thorac Cardiovasc Surg 2002; 123(2):360–361. pmid:11828302
  43. Svensson LG, Kim KH, Lytle BW, Cosgrove DM. Relationship of aortic cross-sectional area to height ratio and the risk of aortic dissection in patients with bicuspid aortic valves. J Thorac Cardiovasc Surg 2003; 126(3):892–893. pmid:14502185
  44. Masri A, Kalahasti V, Svensson LG, et al. Aortic cross-sectional area/height ratio and outcomes in patients with a trileaflet aortic valve and a dilated aorta. Circulation 2016; 134(22):1724–1737. doi:10.1161/CIRCULATIONAHA.116.022995
Issue
Cleveland Clinic Journal of Medicine - 85(6)
Issue
Cleveland Clinic Journal of Medicine - 85(6)
Page Number
481-492
Page Number
481-492
Publications
Publications
Topics
Article Type
Display Headline
Thoracic aortic aneurysm: How to counsel, when to refer
Display Headline
Thoracic aortic aneurysm: How to counsel, when to refer
Legacy Keywords
thoracic aortic aneurysm, aorta, bicuspid aortic valve, Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, dilation, mutations, beta-blockers, dissection, rupture, Frank Cikach, Milind Desai, Eric Roselli, Vidyasagar Kalahasti
Legacy Keywords
thoracic aortic aneurysm, aorta, bicuspid aortic valve, Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, dilation, mutations, beta-blockers, dissection, rupture, Frank Cikach, Milind Desai, Eric Roselli, Vidyasagar Kalahasti
Sections
Inside the Article

KEY POINTS

  • Screening and referral depend on clinical context. A size-based model to determine screening, referral, follow-up, and management serves most cases but should be modified in the context of connective tissue disease or family history of aneurysm and dissection.
  • Medical management involves strict blood pressure and heart rate control with beta-blockers and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Activity modifications should be tailored to the individual, although extreme isometric exercises and heavy lifting should be discouraged.
  • Patients with TAA should be followed up annually, unless the patient is presenting for initial evaluation or significant changes are seen with dedicated imaging.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 05/29/2018 - 11:45
Un-Gate On Date
Tue, 05/29/2018 - 11:45
Use ProPublica
CFC Schedule Remove Status
Tue, 05/29/2018 - 11:45
Hide sidebar & use full width
render the right sidebar.
Article PDF Media